Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 05-08 February 2024

Chair: Sabine Straus – Vice-Chair: Martin Huber
05 February 2024, 13:00 – 19:30, room 1C / via teleconference
06 February 2024, 08:30 – 19:30, room 1C / via teleconference
07 February 2024, 08:30 – 19:30, room 1C / via teleconference
08 February 2024, 08:30 – 16:00, room 1C / via teleconference
Organisational, regulatory and methodological matters (ORGAM)
22 February 2024, 09:00 - 12:00, via teleconference

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to

---

1 Procedure added under 7.2.15 - Respiratory syncytial virus vaccine (bivalent, recombinant) - ABRYSVO (CAP) - EMEA/H/C/006027/MEA 002.1
documents (EMA/127362/2006 Rev.1).
Table of contents

1. Introduction 12
   1.1. Welcome and declarations of interest of members, alternates and experts .......... 12
   1.2. Agenda of the meeting on 05-08 February 2024 .......................................................... 12
   1.3. Minutes of the previous meeting on 08-11 January 2024 ........................................... 12

2. EU referral procedures for safety reasons: urgent EU procedures 12
   2.1. Newly triggered procedures .................................................................................. 12
   2.2. Ongoing procedures ............................................................................................ 12
   2.3. Procedures for finalisation .................................................................................... 12

3. EU referral procedures for safety reasons: other EU referral procedures 12
   3.1. Newly triggered procedures .................................................................................. 12
   3.2. Ongoing procedures ............................................................................................ 13
   3.2.1. Hydroxyprogesterone (NAP) - EMEA/H/A-31/1528 ............................................. 13
   3.3. Procedures for finalisation .................................................................................... 13
   3.4. Re-examination procedures .................................................................................. 13
   3.5. Others .................................................................................................................. 13

4. Signals assessment and prioritisation 13
   4.1. New signals detected from EU spontaneous reporting systems .......................... 13
   4.1.1. Adagrasib – KRAZATI (CAP) .............................................................................. 13
   4.1.2. Methotrexate – NORDIMET (CAP), JYLAMVO (CAP), NAP .......................... 14
   4.1.3. Valaciclovir (NAP) ............................................................................................ 14
   4.2. New signals detected from other sources ......................................................... 14
   4.2.1. Ceftriaxone (NAP) ............................................................................................ 14
   4.2.2. Medroxyprogesterone acetate (NAP) ............................................................... 14
   4.3. Signals follow-up and prioritisation ................................................................. 15
   4.3.1. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/SDA/025; Avelumab - BAVENCIO (CAP) - EMEA/H/C/004338/SDA/011; Cemiplimab - LIBTAYO (CAP) - EMEA/H/C/004844/SDA/010; Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/SDA/005; Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/SDA/012; Ipilimumab – YERVY (CAP) - EMEA/H/C/002213/SDA/048; Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/SDA/056; Nivolumab, relatlimab - OPDUALAG (CAP) - EMEA/H/C/005481/SDA/006; Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/SDA/040; Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/SDA/002; Tremelimumab - IMJUDO (CAP) - EMEA/H/C/006016/SDA/003 ...................................................... 15
   4.3.2. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/SDA/024; Avelumab - BAVENCIO (CAP) - EMEA/H/C/004338/SDA/010; Cemiplimab - LIBTAYO (CAP) - EMEA/H/C/004844/SDA/009; Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/SDA/004; Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/SDA/011; Ipilimumab – YERVY (CAP) - EMEA/H/C/002213/SDA/047; Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/SDA/055; Nivolumab, relatlimab - OPDUALAG (CAP) - EMEA/H/C/005481/SDA/005; Pembrolizumab - KEYTRUDA (CAP) -
4.3. Chlorhexidine (NAP) and other relevant fixed-dose combinations ...................................... 16

4.4. Variation procedure(s) resulting from signal evaluation ........................................ 16

5. Risk management plans (RMPs) .................................................................................. 16

5.1. Medicines in the pre-authorisation phase ................................................................. 16

5.1.1. Capivasertib - (CAP MAA) - EMEA/H/C/006017 ...................................................... 16

5.1.2. Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated - (CAP MAA) -
EMEA/H/C/005797, PRIME ........................................................................................ 16

5.1.3. Eribulin - (CAP MAA) - EMEA/H/C/006191 ............................................................ 16

5.1.4. Fruquintinib - (CAP MAA) - EMEA/H/C/005979 ....................................................... 17

5.1.5. Insulin icodec - (CAP MAA) - EMEA/H/C/005978 ..................................................... 17

5.1.6. Iptacopan - (CAP MAA) - EMEA/H/C/005764, PRIME, Orphan ............................... 17

5.1.7. Omalizumab - (CAP MAA) - EMEA/H/C/005958 ...................................................... 17

5.1.8. Ustekinumab - (CAP MAA) - EMEA/H/C/006415 ..................................................... 17

5.1.9. Ustekinumab - (CAP MAA) - EMEA/H/C/006132 ..................................................... 17

5.1.10. Vibegron - (CAP MAA) - EMEA/H/C/005957 .......................................................... 17

5.2. Medicines in the post-authorisation phase – PRAC-led procedures ....................... 18

5.2.1. Afamelanotide - SCENESSE (CAP) - EMEA/H/C/002548/II/0049, Orphan ............. 18

5.2.2. Esketamine - SPRAVATO (CAP) - EMEA/H/C/004535/II/0021 .............................. 18

5.2.3. Human thrombin, human fibrinogen - TACHOSIL (CAP) - EMEA/H/C/000505/II/0124 .. 18

5.2.4. Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0033 .......................................... 18

5.2.5. Lasmiditan - RAYVOW (CAP) - EMEA/H/C/005332/II/0005 ............................... 19

5.3. Medicines in the post-authorisation phase – CHMP-led procedures ...................... 19

5.3.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/II/0152 ................................. 19

5.3.2. Abrocitinib - CIBINQO (CAP) - EMEA/H/C/005452/II/0010 .............................. 19

5.3.3. Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/II/0022/G ................................. 20

5.3.4. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/II/0083/G .................... 20

5.3.5. Bedaquiline - SIRTURO (CAP) - EMEA/H/C/002614/II/0056, Orphan ....................... 20

5.3.6. Bempedoic acid - NILEMDO (CAP) - EMEA/H/C/004958/II/0031 .......................... 21

5.3.7. Bempedoic acid, ezetimibe - NUSTENDI (CAP) - EMEA/H/C/004959/II/0035 ............. 21

5.3.8. Brentuximab vedotin - ADCETRIS (CAP) - EMEA/H/C/002455/II/0109, Orphan ....... 21

5.3.9. Bulevirtide - HEPCLUDEX (CAP) - EMEA/H/C/004854/II/0031, Orphan ................... 22

5.3.10. Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/II/0034 ................................. 22

5.3.11. Citlacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/II/0021, Orphan .... 22

5.3.12. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) -
EMEA/H/C/005675/II/0096 ....................................................................................... 23

5.3.13. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) -
EMEA/H/C/005675/II/0097 ....................................................................................... 23

5.3.14. Entrectinib - ROZLYTREK (CAP) - EMEA/H/C/004936/X/0017/G ............................ 23
5.3.15. Epcoritamab - TEPKINLY (CAP) - EMA/H/C/005985/II/0001, Orphan ............................................. 24
5.3.16. Faricimab - VABYSMO (CAP) - EMA/H/C/005642/II/0009 ................................................................. 25
5.3.17. Fedratinib - INREBIC (CAP) - EMA/H/C/005026/II/0019, Orphan ............................................... 25
5.3.18. Hydroxyurea carbamide - XROMI (CAP) - EMA/H/C/004837/II/0019 .............................................. 25
5.3.19. Isatuximab - SARCLISA (CAP) - EMA/H/C/004977/II/0026 ............................................................... 25
5.3.20. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - EMA/H/C/005269/WS2551/0043;
    Ivacaftor - KALYDECO (CAP) - EMA/H/C/002494/WS2551/0121 .......................................................... 26
5.3.21. Lenvatinib - KISPLYX (CAP) - EMA/H/C/004224/WS2631/0059; LENVIMA (CAP) - EMA/H/C/003727/WS2631/0054 ............................................................................. 26
5.3.22. Luspatercept - REBLOZYL (CAP) - EMA/H/C/004444/II/0021, Orphan................................. 26
5.3.23. Macitentan - OPSUMIT (CAP) - EMA/H/C/002697/X/0051/G ......................................................... 27
5.3.24. Mirabegron - BETMIGA (CAP) - EMA/H/C/002388/X/0039/G .......................................................... 27
5.3.25. Nintedanib - OFEV (CAP) - EMA/H/C/003821/X/0057/G ................................................................. 27
5.3.27. Patisiran - ONPATTRO (CAP) - EMA/H/C/004699/II/0034, Orphan ...................................................... 28
5.3.28. Peginterferon alfa-2a - PEGASYS (CAP) - EMA/H/C/000395/II/0119/G ........................................... 29
5.3.29. Sotrovimab - XEVUDY (CAP) - EMA/H/C/004977/II/0026 ............................................................... 29
5.3.30. Teriflunomide - TERIFLUNOMIDE ACCORD (CAP) - EMA/H/C/005960/X/0002 ......................... 29
5.3.31. Tisagenlecleucel - KYMRIAH (CAP) - EMA/H/C/004090/II/0075, Orphan ............................... 29

6. Periodic safety update reports (PSURs) ................................................................. 30

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only .......................................................... 30

6.1.1. Acildinium bromide - BRETRARIS GENUAIR (CAP); EKLIRA GENUAIR (CAP) -
    PSUSA/00009005/202307 .................................................................................................................. 30
6.1.2. Ambrisentan - VOLIBRIS (CAP) - PSUSA/00000129/202306 .......................................................... 30
6.1.3. Asfotase alfa - STRENSIQ (CAP) - PSUSA/00010421/202307 .......................................................... 30
6.1.4. Avanafil - SPEDRA (CAP) - PSUSA/00010666/202306 ................................................................. 30
6.1.5. Avapritinib - AYVAKYT (CAP) - PSUSA/00010878/202307 ............................................................ 30
6.1.6. Beclometasone, formoterol, glycopyrronium bromide - RIARIFY (CAP); TRIMBOW (CAP);
    TRYDONIS (CAP) - PSUSA/00010617/202307 .............................................................................. 31
6.1.7. Birch bark extract - FILSUVEZ (CAP) - PSUSA/00010446/202307 .......................................................... 31
6.1.8. Brexucabtagene autoleucel - TECARTUS (CAP) - PSUSA/00010903/202307 ......................... 31
6.1.9. Budesonide - JORVEZA (CAP) - PSUSA/00010634/202307 ............................................................. 31
6.1.10. Carfilzomib - KYPROLIS (CAP) - PSUSA/00010448/202307 .......................................................... 31
6.1.11. Casirivimab, imdevimab - RONAPREVE (CAP) - PSUSA/00010963/202307 ................................. 32
6.1.12. Cenegermin - JORVEZA (CAP) - PSUSA/00010624/202307 .......................................................... 32
6.1.13. Cladribine - MAVENCLAD (CAP) - PSUSA/00010634/202307 ...................................................... 32
6.1.15. Eptacog beta (activated) - CEVENFACTA (CAP) - PSUSA/00011006/202307 ......................... 32
6.1.16. Faricimab - VABYSMO (CAP) - PSUSA/00011016/202307 ............................................................. 33
| 6.1.17. | Finerenone - KERENDIA (CAP) | PSUSA/00010978/202307 | 33 |
| 6.1.18. | Glucagon - BAQSIMI (CAP); OGLUO (CAP) | PSUSA/00010826/202307 | 33 |
| 6.1.19. | Glucarpidase - VORAXAZE (CAP) | PSUSA/00010968/202307 | 33 |
| 6.1.20. | Guselkumab - TREMFYA (CAP) | PSUSA/00010652/202307 | 33 |
| 6.1.21. | Human C1-esterase inhibitor - CINRYZE (CAP) | PSUSA/00010104/202306 | 33 |
| 6.1.22. | Icosapent ethyl - VAZKEPA (CAP) | PSUSA/00010922/202307 | 34 |
| 6.1.23. | Imipenem, cilastatin, relebactam - RECARBRIO (CAP) | PSUSA/00010830/202307 | 34 |
| 6.1.24. | Indacaterol, glycopyrronium, mometasone - ENERZAIR BREEZHALER (CAP); ZIMBUS BREEZHALER (CAP) | PSUSA/00010861/202307 | 34 |
| 6.1.25. | Inotersen - TEGSEDI (CAP) | PSUSA/00010697/202307 | 34 |
| 6.1.26. | L-lysine hydrochloride, l-arginine hydrochloride - LYSAKARE (CAP) | PSUSA/00010786/202307 | 34 |
| 6.1.27. | Neratinib - NERLYNX (CAP) | PSUSA/00010712/202307 | 35 |
| 6.1.28. | Nirmatrelvir, ritonavir - PAXLOVID (CAP) | PSUSA/00010984/202306 | 35 |
| 6.1.29. | Nonacog gamma - RIXUBIS (CAP) | PSUSA/00010320/202307 | 35 |
| 6.1.30. | Odevixibat - BYLVAY (CAP) | PSUSA/00010949/202307 | 35 |
| 6.1.31. | Peginterferon alfa-2a - PEGASYS (CAP) | PSUSA/00010830/202307 | 35 |
| 6.1.32. | Pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed) - VAXNEUVANCE (CAP) | PSUSA/00010968/202307 | 35 |
| 6.1.33. | Relugolix - ORGOVYX (CAP) | PSUSA/00010994/202307 | 36 |
| 6.1.34. | Remimazolam - BYFAVO (CAP) | PSUSA/00010924/202307 | 36 |
| 6.1.35. | Spheroids of human autologous matrix-associated chondrocytes - SPHEROX (CAP) | PSUSA/00010630/202307 | 36 |
| 6.1.36. | Tasimelteon - HETLIOZ (CAP) | PSUSA/00010394/202307 | 36 |
| 6.1.37. | Tebentafusp - KIMMTRAK (CAP) | PSUSA/00010991/202307 | 36 |
| 6.1.38. | Tecovirimat - TECOVIRIMAT SIGA (CAP) | PSUSA/00010991/202307 | 36 |
| 6.1.40. | Tigecycline - TYGACIL (CAP) | PSUSA/00000954/202306 | 37 |
| 6.1.41. | Vericiguat - VERQUVO (CAP) | PSUSA/00010950/202307 | 37 |
| 6.1.42. | Voclosporin - LUPKYNIS (CAP) | PSUSA/00011020/202307 | 37 |
| 6.1.43. | Voretigene neparvovec - LUXTURNA (CAP) | PSUSA/00010742/202307 | 37 |
| 6.2. | PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) | | 38 |
| 6.2.1. | Caffeine - GENCEBOK (CAP); PEYONA (CAP); NAP | PSUSA/00000482/202307 | 38 |
| 6.3. | PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only | | 38 |
| 6.3.1. | Acetylsalicylic acid, rosuvastatin (NAP) | PSUSA/00010893/202306 | 38 |
| 6.3.2. | Allergen for therapy: betula verrucosa (NAP) | PSUSA/00010815/202307 | 38 |
| 6.3.3. | Almotriptan (NAP) | PSUSA/00000101/202307 | 38 |
| 6.3.4. | Cyproterone (NAP) | PSUSA/00000950/202307 | 38 |
| 6.3.5. | Diclofenac, misoprostol (NAP) | PSUSA/0001040/202307 | 39 |
6.3.6. Epirubicin (NAP) - PSUSA/00001234/202306 .............................................................. 39
6.3.7. Ferucarbotran (NAP) - PSUSA/00001382/202306 ........................................................ 39
6.3.8. Hepatitis A (inactivated), typhoid polysaccharide vaccine (adsorbed) (NAP) - PSUSA/00001594/202306 .......................................................... 39
6.3.9. Ibuprofen, pseudoephedrine (NAP) - PSUSA/00001711/202307 ............................... 39
6.3.10. Levoctetirizine (NAP) - PSUSA/00001850/202307 ......................................................... 40
6.3.11. Misoprostol (NAP) - PSUSA/00010291/202306 ............................................................ 40
6.3.12. Nimesulide (NAP) - PSUSA/00002165/202306 ............................................................. 40
6.3.13. Octreotide (NAP) - PSUSA/00002201/202306 ............................................................. 40
6.3.14. Oxycodone hydrochloride, paracetamol (NAP) - PSUSA/00002256/202307 ..................... 40
6.3.15. Oxytocin (NAP) - PSUSA/00010913/202306................................................................. 40
6.3.16. Oxytocin (NAP) - PSUSA/00010914/202306 ................................................................. 40
6.3.17. Paracetamol, pseudoephedrine (NAP) - PSUSA/00002307/202306 ................................. 41
6.3.18. Phentermine, topiramate (NAP) - PSUSA/00010956/202307 ......................................... 41
6.3.19. Pseudoephedrine (NAP); acetylsalicylic acid, pseudoephedrine (NAP) - PSUSA/00010667/202306 ........................................................... 41
6.3.20. Rizatriptan (NAP) - PSUSA/00002655/202306 ............................................................. 41
6.3.21. Tramadol (NAP) - PSUSA/00003002/202306 ............................................................... 42

6.4. Follow-up to PSUR/PSUSA procedures ................................................................. 42
6.4.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/LEG 071 ........................................... 42
6.4.2. Piperaquine tetraphosphate, arteminol - EURARTESIM (CAP) - EMEA/H/C/001199/LEG 018.142
6.4.3. Tocilizumab - ROACTEMRA (CAP) - EMEA/H/C/000955/LEG 063.1 .................................. 42
6.4.4. Vernakalant - BRINAVESS (CAP) - EMEA/H/C/001215/LEG 034 ..................................... 43

6.5. Variation procedure(s) resulting from PSUSA evaluation ..................................... 43
6.5.1. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0054, Orphan ......................... 43
6.5.2. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/II/0063 ........................................................ 43
6.5.3. Rituximab - MABTHERA (CAP) - EMEA/H/C/000165/II/0201/G ...................................... 43

6.6. Expedited summary safety reviews ...................................................................... 44

7. Post-authorisation safety studies (PASS) 44
7.1. Protocols of PASS imposed in the marketing authorisation(s).............................. 44
7.2. Protocols of PASS non-imposed in the marketing authorisation(s) ...................... 44
7.2.1. Agalsidase beta - FABRAZYME (CAP) - EMEA/H/C/000370/MEA 065 ...................... 44
7.2.2. Atogepant - AQUIPTA (CAP) - EMEA/H/C/005871/MEA 002 ........................................... 44
7.2.3. Birch bark extract - FILSUVEZ (CAP) - EMEA/H/C/005035/MEA 001.2 .................... 45
7.2.4. Cinacalcet - MIMPARA (CAP) - EMEA/H/C/000570/MEA 035.8 ................................. 45
7.2.5. Coronavirus (COVID-19) vaccine (B.1.351 variant, prefusion Spike delta TM protein, recombinant) - VIDPREVTYN BETA (CAP) - EMEA/H/C/005754/MEA 002.3 ................... 45
7.2.6. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/MEA 012.1 ............................ 45
7.2.7. Enfortumab vedotin - PADCEV (CAP) - EMEA/H/C/005392/MEA 003.1 .................... 46
7.2.8. Filgotinib - JYSELECA (CAP) - EMEA/H/C/005113/MEA 017.1 ........................................ 46
7.2.9. Linzagolix choline - YSELTY (CAP) - EMEA/H/C/005442/MEA 002.2 ......................... 46
7.2.10. Mirikizumab - OMVOH (CAP) - EMEA/H/C/005122/MEA 001 .............................. 46
7.2.11. Mirikizumab - OMVOH (CAP) - EMEA/H/C/005122/MEA 002 ............................. 47
7.2.12. Naldemedine - RIZMOIC (CAP) - EMEA/H/C/004256/MEA 001.6 ......................... 47
7.2.13. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/MEA 005.7 ......................... 47
7.2.14. Pitolisant - OZAWADE (CAP) - EMEA/H/C/005117/MEA 003.2 ......................... 47
7.3. Results of PASS imposed in the marketing authorisation(s) ........................................ 48
7.4. Results of PASS non-imposed in the marketing authorisation(s) ................................... 48
7.4.1. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/WS2587/0085; Diroximel fumarate - VUMERITY (CAP) - EMEA/H/C/005437/WS2587/0015 ......................... 48
7.4.2. Dolutegravir, lamivudine - DOVATO (CAP) - EMEA/H/C/004909/WS2620/0047; Dolutegravir, Rilpivirine - JULUCA (CAP) - EMEA/H/C/004427/WS2620/0056; Dolutegravir - TIVICAY (CAP) - EMEA/H/C/002753/WS2620/0092; Dolutegravir, Abacavir, Lamivudine - TRIUMEQ (CAP) - EMEA/H/C/002754/WS2620/0118 ......................................................... 48
7.4.3. Epoetin alfa - ABSEAMED (CAP) - EMEA/H/C/000727/WS2615/0108; Epoetin alfa - BINOCRIT (CAP) - EMEA/H/C/000725/WS2615/0108; Epoetin alfa - EPOETIN ALFA HEXAL (CAP) - EMEA/H/C/000726/WS2615/0108 ......................................................... 49
7.4.4. Hepatitis B surface antigen (rDNA) - HEPLISAV B (CAP) - EMEA/H/C/005063/II/0031 ...... 49
7.4.5. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/II/0101/G .............................. 49
7.4.6. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/II/0081 .............................. 50
7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation .............................................................. 50
7.5.1. Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/MEA 007.5 .................................. 50
7.5.2. Naxolegol - MOVENTIG (CAP) - EMEA/H/C/002810/MEA 006.15 ......................... 50
7.5.3. Risdiplam - EVRYSDI (CAP) - EMEA/H/C/005145/MEA 007.4 ................................ 50
7.5.4. Rivaroxaban - XARELTO (CAP) - EMEA/H/C/000944/MEA 049.4 ......................... 51
7.5.5. Siponimod - MAYZENT (CAP) - EMEA/H/C/004712/MEA 004.4 ......................... 51
7.5.6. Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/MEA 032.4 ......................... 51
7.5.7. Tacrolimus - MODIGRAF (CAP) - EMEA/H/C/000954/MEA 024.4 ......................... 51
7.5.8. Teduglutide - REVESTIVE (CAP) - EMEA/H/C/002345/ANX 003.11 ..................... 52
7.6. Others .................................................................................................................. 52
7.7. New Scientific Advice ........................................................................................... 52
7.8. Ongoing Scientific Advice ..................................................................................... 52
7.9. Final Scientific Advice (Reports and Scientific Advice letters) .............................. 52
8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 52
8.1. Annual reassessments of the marketing authorisation ........................................ 52
8.1.1. Cholic acid - ORPHACOL (CAP) - EMEA/H/C/001250/S/0053 (without RMP) ........ 52
8.1.2. Eladocagene exuparvovec - UPSTAZA (CAP) - EMEA/H/C/005352/S/0017 (without RMP) .... 52
8.1.3. Fosdenopterin - NULIBRY (CAP) - EMEA/H/C/005378/S/0006 (without RMP) ............ 53
8.1.4. Idebenone - RAXONE (CAP) - EMEA/H/C/003834/S/0035 (without RMP) ....................... 53
8.1.5. Lomitapide - LOJUXTA (CAP) - EMEA/H/C/002578/S/0057 (without RMP) .................. 53
8.1.6. Obiltoxaximab - NYXTHRACIS (CAP) - EMEA/H/C/005169/S/0013 (without RMP) ....... 53
8.1.7. Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) - EMEA/H/C/002596/S/0095 (without RMP) ......................................................... 53
8.1.8. Tocofersolan - VEDROP (CAP) - EMEA/H/C/000920/S/0049 (without RMP) ............... 54

8.2. Conditional renewals of the marketing authorisation ........................................... 54
8.2.1. Mosunetuzumab - LUNSUMIO (CAP) - EMEA/H/C/005680/R/0008 (without RMP) ....... 54
8.2.2. Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - PANDEMIC INFLUENZA VACCINE H5N1 ASTRAZENECA (CAP) - EMEA/H/C/003963/R/0071 (without RMP) ............... 54
8.2.3. Selumetinib - KOSELUGO (CAP) - EMEA/H/C/005244/R/0015 (without RMP) ............ 54

8.3. Renewals of the marketing authorisation .......................................................... 54
8.3.1. Idelalisib - ZYDELIG (CAP) - EMEA/H/C/003843/R/0059 (with RMP) .......................... 54
8.3.2. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/R/0020 (without RMP) .... 55
8.3.3. L-lysine hydrochloride, l-arginine hydrochloride - LYSAKARE (CAP) - EMEA/H/C/004541/R/0016 (without RMP) .......................................................... 55
8.3.4. Pegfilgrastim - GRASUSTEK (CAP) - EMEA/H/C/004556/R/0014 (with RMP) ............ 55
8.3.5. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/R/0038 (without RMP) ................. 55
8.3.6. Posaconazole - POSACONAZOLE ACCORD (CAP) - EMEA/H/C/005005/R/0014 (with RMP) 55
8.3.7. Posaconazole - POSACONAZOLE AHCL (CAP) - EMEA/H/C/005028/R/0011 (without RMP) 55
8.3.8. Ravulizumab - ULTOMIRIS (CAP) - EMEA/H/C/004954/R/0040 (without RMP) .......... 56
8.3.9. Talazoparib - TALZENNA (CAP) - EMEA/H/C/004674/R/0040 (without RMP) ............. 56

9. Product related pharmacovigilance inspections 56
9.1. List of planned pharmacovigilance inspections ..................................................... 56
9.2. Ongoing or concluded pharmacovigilance inspections ........................................ 56
9.3. Others .................................................................................................................. 56

10. Other safety issues for discussion requested by the CHMP or the EMA 56
10.1. Safety related variations of the marketing authorisation ........................................... 56
10.2. Timing and message content in relation to Member States’ safety announcements 57
10.3. Other requests .................................................................................................... 57
10.4. Scientific Advice ............................................................................................... 57

11. Other safety issues for discussion requested by the Member States 57
11.1. Safety related variations of the marketing authorisation ........................................... 57
11.1.1. Methotrexate (NAP) - SE/H/1442/01-02/II/27, SE/H/1422/01/II/20 .............................. 57
11.2. Other requests .................................................................................................... 57

12. Organisational, regulatory and methodological matters 57
12.1. Mandate and organisation of the PRAC ............................................................ 57
12.1.1. PRAC membership ................................................................................................... 57
12.1.2. Vote by proxy ......................................................................................................... 58
12.2. Coordination with EMA Scientific Committees or CMDh-v ............................... 58
12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ...... 58
12.4. Cooperation within the EU regulatory network ..................................................... 58
12.4.1. Health threats and EMAEmergency Task Force (ETF) activities - update .......... 58
12.5. Cooperation with International Regulators .......................................................... 58
12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee ............................................................. 58
12.7. PRAC work plan .................................................................................................... 58
12.8. Planning and reporting ......................................................................................... 58
12.8.1. EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q4 2023 and predictions ...................................................... 58
12.9. Pharmacovigilance audits and inspections ............................................................ 58
12.9.1. Pharmacovigilance systems and their quality systems ........................................ 58
12.9.2. Pharmacovigilance inspections ........................................................................... 59
12.9.3. Pharmacovigilance audits .................................................................................. 59
12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list .... 59
12.10.1. Periodic safety update reports ............................................................................ 59
12.10.2. Granularity and Periodicity Advisory Group (GPAG) ....................................... 59
12.10.3. PSURs repository ............................................................................................. 59
12.10.4. Union reference date list – consultation on the draft list .................................. 59
12.11. Signal management ............................................................................................ 59
12.11.2. Signals and safety analytics project – update on activities .................................. 59
12.12. Adverse drug reactions reporting and additional reporting ............................... 59
12.12.1. Management and reporting of adverse reactions to medicinal products .......... 59
12.12.2. Additional monitoring ...................................................................................... 60
12.12.3. List of products under additional monitoring – consultation on the draft list ...... 60
12.13. EudraVigilance database ..................................................................................... 60
12.13.1. Activities related to the confirmation of full functionality ................................... 60
12.14.1. Risk management systems ............................................................................... 60
12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations ........... 60
12.15. Post-authorisation safety studies (PASS) ........................................................... 60
12.15.1. Post-authorisation Safety Studies – imposed PASS ............................................ 60
12.15.2. Post-authorisation Safety Studies – non-imposed PASS ..................................... 60
12.16. Community procedures ....................................................................................... 60
12.16.1. Referral procedures for safety reasons ......................................................... 60
12.17. Renewals, conditional renewals, annual reassessments ................................. 60
12.18. Risk communication and transparency .......................................................... 61
  12.18.1. Public participation in pharmacovigilance ......................................................... 61
  12.18.2. Safety communication ................................................................................. 61
12.19. Continuous pharmacovigilance ........................................................................ 61
  12.19.1. Incident management .................................................................................. 61
12.20. Impact of pharmacovigilance activities ............................................................. 61
12.21. Others ........................................................................................................... 61
  12.21.2. Direct healthcare professional communications (DHPCs) process review and publication on EMA website ........................................................... 61
  12.21.3. Drafting group on multiple sclerosis and and use of disease modifying drugs (DMDs) in women of childbearing potential – update ........................................... 61
  12.21.4. Drafting group on standard product information wording - Haemophagocytic Lymphohistiocytosis (HLH) -update ................................................................. 61
  12.21.5. EMA-HMA Lessons Learned from COVID-19 Pandemic ................................. 62
  12.21.6. International Conference on Harmonisation (ICH) E2D(R1) - Post-approval safety data management: definitions and standards for expedited reporting - update .... 62
  12.21.7. Pharmacovigilance business team - activities and work plan .......................... 62
  12.21.8. PRAC Assessors trainings - update ................................................................. 62
  12.21.9. Rules for granting companies extended clock-stops – proposal for review .......... 62

13. Any other business .................................................................................................. 62

14. Explanatory notes ................................................................................................... 62
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 05-08 February 2024. See February 2024 PRAC minutes (to be published post March 2024 PRAC meeting).

1.2. **Agenda of the meeting on 05-08 February 2024**

*Action:* For adoption

1.3. **Minutes of the previous meeting on 08-11 January 2024**

*Action:* For adoption

2. **EU referral procedures for safety reasons: urgent EU procedures**

2.1. **Newly triggered procedures**

None

2.2. **Ongoing procedures**

None

2.3. **Procedures for finalisation**

None

3. **EU referral procedures for safety reasons: other EU referral procedures**

3.1. **Newly triggered procedures**

None
3.2. Ongoing procedures

3.2.1. Hydroxyprogesterone (NAP) - EMEA/H/A-31/1528

Applicant(s): various
PRAC Rapporteur: Amelia Cupelli; PRAC Co-rapporteur: Nathalie Gault
Scope: Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data
Action: Ad-hoc expert group (AHEG) meeting feedback and for adoption of a list of outstanding issues (LoOI)

3.3. Procedures for finalisation

None

3.4. Re-examination procedures2

None

3.5. Others

None

4. Signals assessment and prioritisation3

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Adagrasib – KRAZATI (CAP)

Applicant: Mirati Therapeutics B.V.
PRAC Rapporteur: Kimmo Jaakkola
Scope: Signal of serious cutaneous adverse reactions (SCARs)
Action: For adoption of PRAC recommendation
EPITT 20051 – New signal
Lead Member State(s): FI

---

2 Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
3 Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required
4.1.2. **Methotrexate – NORDIMET (CAP), JYLAMVO (CAP), NAP**

Applicant: Nordic Group B.V. (Nordimet), Therakind (Europe) Limited (Jylamvo)
PRAC Rapporteur: to be appointed
Scope: Signal of hyperhomocysteinaemia

**Action:** For adoption of PRAC recommendation
EPITT 20031 – New signal
Lead Member State(s): DE

4.1.3. **Valaciclovir (NAP)**

Applicant: various
PRAC Rapporteur: to be appointed
Scope: Signal of acute hepatitis

**Action:** For adoption of PRAC recommendation
EPITT 20047 – New signal
Lead Member State(s): CZ

4.2. **New signals detected from other sources**

4.2.1. **Ceftriaxone (NAP)**

Applicant: various
PRAC Rapporteur: to be appointed
Scope: Signal of precipitation when administered with calcium-containing solutions in infants between 29 days and 1 year

**Action:** For adoption of PRAC recommendation
EPITT 1964 – New signal
Lead Member State(s): LV

4.2.2. **Medroxyprogesterone acetate (NAP)**

Applicant: various
PRAC Rapporteur: to be appointed
Scope: Signal of meningioma

**Action:** For adoption of PRAC recommendation
EPITT 20030 – New signal
Lead Member State(s): NL
4.3. Signals follow-up and prioritisation

4.3.1. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/SDA/025; Avelumab - BAVENCIO (CAP) - EMEA/H/C/004338/SDA/011; Cemiplimab - LIBTAYO (CAP) - EMEA/H/C/004844/SDA/010; Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/SDA/005; Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/SDA/012; Ipilimumab – YERVOY (CAP) - EMEA/H/C/002213/SDA/048; Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/SDA/056; Nivolumab, relatlimab - OPDUALAG (CAP) - EMEA/H/C/005481/SDA/006; Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/SDA/040; Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/SDA/002; Tremelimumab - IMJUDO (CAP) - EMEA/H/C/006016/SDA/003

Applicant: Bristol-Myers Squibb Pharma EEIG (Imfinzi, Opdivo, Opdualag), GlaxoSmithKline (Ireland) Limited (Jemperli), Merck Europe B.V. (Bavencio), Merck Sharp & Dohme B.V.(Keytruda), Novartis Europharm Limited (Tevimbra), Regeneron Ireland Designated Activity Company (Libtayo), Roche Registration GmbH (Tecentriq)

PRAC Rapporteur: Bianca Mulder

Scope: Signal of coeliac disease

**Action:** For adoption of PRAC recommendation

EPITT 19958 – Follow-up to September 2023

4.3.2. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/SDA/024; Avelumab - BAVENCIO (CAP) - EMEA/H/C/004338/SDA/010; Cemiplimab - LIBTAYO (CAP) - EMEA/H/C/004844/SDA/009; Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/SDA/004; Durvalumab - IMFINZI (CAP) - EMEA/H/C/004771/SDA/011; Ipilimumab – YERVOY (CAP) - EMEA/H/C/002213/SDA/047; Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/SDA/055; Nivolumab, relatlimab - OPDUALAG (CAP) - EMEA/H/C/005481/SDA/005; Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/SDA/039; Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/SDA/001; Tremelimumab - IMJUDO (CAP) - EMEA/H/C/006016/SDA/002

Applicant(s): AstraZeneca AB (Imjudo), Bristol-Myers Squibb Pharma EEIG (Imfinzi, Opdivo, Opdualag), GlaxoSmithKline (Ireland) Limited (Jemperli), Merck Europe B.V. (Bavencio), Merck Sharp & Dohme B.V.(Keytruda), Novartis Europharm Limited (Tevimbra), Regeneron Ireland Designated Activity Company (Libtayo), Roche Registration GmbH (Tecentriq)

PRAC Rapporteur: Martin Huber

Scope: Signal of pancreatic failure

**Action:** For adoption of PRAC recommendation

EPITT 19955 – Follow-up to September 2023

---

4 Held 28 August – 31 August 2023
5 Held 28 August – 31 August 2023
4.3.3. Chlorhexidine (NAP)\(^6\) and other relevant fixed-dose combinations\(^7\)

Applicant: various
PRAC Rapporteur: Lina Seibokiene
Scope: Signal of persistent corneal injury and significant visual impairment

**Action:** For adoption of PRAC recommendation
EPITT 19970 – Follow-up to October 2023\(^8\)

4.4. Variation procedure(s) resulting from signal evaluation

None

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Capivasertib - (CAP MAA) - EMEA/H/C/006017

Scope (pre D-180 phase): Indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH−) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated - (CAP MAA) - EMEA/H/C/005797, PRIME

Scope (pre D-120 phase, accelerated assessment): prevention of disease caused by chikungunya (CHIKV) virus

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

\(^6\) For cutaneous use only
\(^7\) Chlorhexidine, chlorocresol, hexamidine; chlorhexidine gluconate, chlorocresol, hexamidine; chlorocresol, hexamidine, chlorhexidine digluconate; benzalkonium chloride, chlorhexidine gluconate; chlorhexidine gluconate, benzoxonium chloride, retinol; benzalkonium chloride, chlorhexidine gluconate, benzyl alcohol; chlorhexidine gluconate; chlorhexidine gluconate, chlorhexidine gluconate, cetrimonium; chlorhexidine gluconate, chlorocresol, hexamidine; chlorhexidine gluconate, dexpanthenol; chlorhexidine gluconate, hydrocortisone; chlorhexidine gluconate, hydrogen peroxide, isopropyl alcohol; chlorhexidine gluconate, isopropyl alcohol; chlorhexidine gluconate, ethanol; chlorhexidine gluconate, phenol; benzalkonium chloride, chlorhexidine gluconate; benzalkonium chloride, chlorhexidine digluconate; chlorhexidine digluconate, isopropyl alcohol; chlorhexidine digluconate, benzyl alcohol; chlorhexidine digluconate, isopropyl alcohol; chlorhexidine digluconate, ethanol; chlorhexidine digluconate, phenol; chlorhexidine digluconate, isopropyl alcohol; chlorhexidine digluconate, benzyl alcohol; chlorhexidine digluconate, isopropyl alcohol; chlorhexidine digluconate, benzyl alcohol; chlorhexidine digluconate, isopropyl alcohol; chlorhexidine dihydrochloride, liquid paraffin; chlorhexidine dihydrochloride, dexpanthenol; chlorhexidine dihydrochloride, nystatin; chlorhexidine dihydrochloride, nystatin, dexamethasone; chlorhexidine dihydrochloride, nystatin, hydrocortisone; chlorhexidine dihydrochloride, zinc oxide, pramcine hydrochloride; triamcinolone acetonide; chlorhexidine dihydrochloride, dexpanthenol, alphaphospherol acetate, vitamin A; chlorhexidine gluconate; cetrimide, chlorhexidine digluconate; chlorhexidine acetate; cetrimide, chlorhexidine acetate; chlorhexidine acetate; retinol palmitate, benzocaine, retinol, chlorhexidine acetate; bacitracin zinc, chlorhexidine acetate; nystatin, hydrocortisone, chlorhexidine acetate.

\(^8\) Held 25 September – 29 September 2023
5.1.3. **Eribulin - (CAP MAA) - EMEA/H/C/006191**

Scope (pre D-180 phase): treatment of breast cancer and liposarcoma  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. **Fruquintinib - (CAP MAA) - EMEA/H/C/005979**

Scope (pre D-180 phase): treatment of metastatic colorectal cancer  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. **Insulin icodec - (CAP MAA) - EMEA/H/C/005978**

Scope (pre D-180 phase): treatment of diabetes mellitus in adults  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. **Iptacopan - (CAP MAA) - EMEA/H/C/005764, PRIME, Orphan**

Applicant: Novartis Europharm Limited  
Scope (pre D-180 phase): treatment of paroxysmal nocturnal haemoglobinuria  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. **Omalizumab - (CAP MAA) - EMEA/H/C/005958**

Scope (pre D-180 phase): treatment of asthma  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. **Ustekinumab - (CAP MAA) - EMEA/H/C/006415**

Scope (pre D-180 phase): treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults, treatment of Crohn’s Disease  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.9. **Ustekinumab - (CAP MAA) - EMEA/H/C/006132**

Scope (pre D-180 phase): treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults, treatment of Crohn’s Disease and ulcerative colitis  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.10. **Vibegron - (CAP MAA) - EMEA/H/C/005957**

Scope (pre D-180 phase): treatment of micturition frequency and/or urgency incontinence as may occur in adult patients with Over Active Bladder (OAB) syndrome.  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Afamelanotide - SCENESSE (CAP) - EMEA/H/C/002548/II/0049, Orphan

Applicant: Clinuvel Europe Limited
PRAC Rapporteur: Martin Huber
Scope: Submission of the final report from study CUV-RCR-001 (Scenesse (Afamelanotide 16mg) Retrospective Chart Review) listed as an obligation in the Annex II of the product information. This is a retrospective study comparing long term safety data and outcome endpoints in patients receiving and not receiving Scenesse, or having discontinued Scenesse use. The Annex II and the RMP (version 9.6) are updated accordingly

Action: For adoption of PRAC Assessment Report

5.2.2. Esketamine - SPRAVATO (CAP) - EMEA/H/C/004535/II/0021

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Kirsti Villikka
Scope: Submission of an updated RMP version 5.2 in order to remove "use during pregnancy" as missing information from the list of safety concerns, with the consequential removal of the associated category 3 additional pharmacovigilance activity, the National Pregnancy Registry for Antidepressants ("Massachusetts General Hospital (MGH) pregnancy registry)

Action: For adoption of PRAC Assessment Report

5.2.3. Human thrombin, human fibrinogen - TACHOSIL (CAP) - EMEA/H/C/000505/II/0124

Applicant: Corza Medical GmbH
PRAC Rapporteur: Gabriele Maurer
Scope: Submission of an updated RMP version 9.1 in order to reflect the extension of indication to include the paediatric population and to update the details of the planned non-interventional PASS: PASS-TachoSil Evaluation (PasTel)

Action: For adoption of PRAC Assessment Report

5.2.4. Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0033

Applicant: Sandoz GmbH
PRAC Rapporteur: Mari Thorn
Scope: Submission of an updated RMP version 4.0 in order to remove the UKIBD (UK) registry from the additional pharmacovigilance activities

Action: For adoption of PRAC Assessment Report
5.2.5. Lasmiditan - RAYVOW (CAP) - EMEA/H/C/005332/II/0005

Applicant: Eli Lilly Nederland B.V.
PRAC Rapporteur: Anna Mareková
Scope: Submission of an updated RMP version 1.1 in order to include a descriptive interim analysis in the study design of study H8H-MC-B006, listed as a category 3 study in the RMP. This is a non-interventional study titled ‘Lasmiditan Use and Motor Vehicle Accidents in Real-World Settings in the US’
Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/II/0152

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Kimmo Jaakkola
Scope: Extension of indication to include the prophylaxis of acute Graft versus Host Disease (aGvHD) in the adult and paediatric population for Orencia, based on final results from studies IM101311 - Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis and IM101841 - Overall Survival In 7/8 HLA-Matched Hematopoietic Stem Cell Transplantation Patients Treated With Abatacept Combined With A Calcineurin Inhibitor And Methotrexate - An Analysis Of The Center For International Blood And Marrow Transplant Research (Cibmr) database. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and Labelling are updated in accordance. Version 28.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. Abrocitinib - CIBINQO (CAP) - EMEA/H/C/005452/II/0010

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Petar Mas
Scope: Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis for CIBINQO based on final results from non-clinical study 00655292 [21GR211] and interim results from clinical study B7451015; this is a Phase III multi-centre, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.3. Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/II/0022/G

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Bianca Mulder
Scope: Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.2, 4.4, 4.8 of the SmPC in order to update information on prophylactic use of metformin for hyperglycaemia based on the results from study CBYL719CES01T (METALLICA). METALLICA is a Phase II study aimed to evaluate the effect of prophylactic use of metformin for hyperglycaemia in HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer patients treated with alpelisib plus endocrine therapy.
- Update of section 4.8 of the SmPC in order to add “uveitis” to the list of adverse drug reactions (ADRs) with frequency “Not known” based on a cumulative review of the MAH safety database and literature.

The package leaflet and Annex II are updated accordingly. The RMP version 7.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/II/0083/G

Applicant: Roche Registration GmbH
PRAC Rapporteur: Carla Torre
Scope: A grouped application comprising of 2 Type II variations, as follows:
- C.I.4: Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study IMvigor210 (GO29293) listed as a PAES in the Annex II; this is a Phase II, multicentre, single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancer. The Annex II is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and to bring it in line with the latest QRD template.
- C.I.13: Submission of the final report from study SAUL (MO29983) listed as a category 3 study in the RMP. This is an open-label, single arm, multicentre, safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract. The RMP version 30.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Bedaquiline - SIRTURO (CAP) - EMEA/H/C/002614/II/0056, Orphan

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Extension of indications by removal of the restriction for use of SIRTURO (bedaquiline [BDQ]), based on final results from study STREAM Stage 2; this is an multicentre, open-label, parallel-group, randomised, active-controlled study in participants aged 15 years or older with RR/MDR-TB to evaluate an investigational BDQ-containing, all-oral, 40-week regimen of anti-TB drugs (Regimen C) compared to an injectable-containing
40-week control regimen (Regimen B). As a consequence of the data emerging from the submitted study, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. In addition, section E of Annex II has also been updated. The labelling and package leaflet are updated in accordance. Version 10.1 of the RMP has also been submitted. Furthermore, the product information is brought in line with the latest QRD template version 10.3. As part of the application, the MAH is requesting the switch from a conditional MA to standard MA

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.6. Bempedoic acid - NILEMDO (CAP) - EMEA/H/C/004958/II/0031

**Applicant:** Daiichi Sankyo Europe GmbH  
**PRAC Rapporteur:** Kimmo Jaakkola  
**Scope:** Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk, based on results from study 1002-043 (CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen]). CLEAR outcomes study is a phase 3 multi-centre randomised, double-blind, placebo-controlled study to evaluate whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly. Version 4.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor formatting changes to the product information. As part of the application, the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7. Bempedoic acid, ezetimibe - NUSTENDI (CAP) - EMEA/H/C/004959/II/0035

**Applicant:** Daiichi Sankyo Europe GmbH  
**PRAC Rapporteur:** Kimmo Jaakkola  
**Scope:** Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk for NUSTENDI, based on results from Study 1002-043, known as the CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen] outcomes trial, a phase 3, randomised, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.8. Brentuximab vedotin - ADCETRIS (CAP) - EMEA/H/C/002455/II/0109, Orphan

**Applicant:** Takeda Pharma A/S
PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication to include in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) for ADCETRIS based on the final overall survival results of Echelon-2 (SGN035-014): a randomised, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 19.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Bulevirtide - HEPCLUDEX (CAP) - EMEA/H/C/004854/II/0031, Orphan

Applicant: Gilead Sciences Ireland Unlimited Company

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension of indication to include treatment of chronic hepatitis delta virus (HDV) infection in paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease for Hepcludex, based on a modelling and simulation study and an extrapolation study to evaluate the use of Bulevirtide for the treatment of chronic hepatitis D infection in children from 3 to less than 18 years of age. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The package leaflet has been updated accordingly. Version 4.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/II/0034

Applicant: Gedeon Richter Plc.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Update of sections 4.3 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The package leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Ciltacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/II/0021, Orphan

Applicant: Janssen-Cilag International NV, ATMP

PRAC Rapporteur: Jo Robays
Scope: Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD and a product information, have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomised, open-label, multicentre study to determine whether treatment with ciltacel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the product information. As part of the application the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

### 5.3.12. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/II/0096

- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Jean-Michel Dogné

Scope: Update of sections 4.8 and 5.1 of the SmPC based on final results from study D7220C00001; this is a phase 2/3 partially double-blinded, randomised, multinational, active-controlled study in both previously vaccinated and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of SARS-CoV-2. The RMP version 8 s1 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.13. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/II/0097

- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Jean-Michel Dogné

Scope: Submission of the final report from study D8110C00001 listed as a category 3 study in the RMP (SOB/020). This is a phase III, randomised, placebo-controlled study of AZD1222 (Vaxzevria) conducted in the US, Peru and Chile. The purpose of the final CSR addendum is to provide long-term safety data through to study completion and include the second year of follow-up post-first dose and final day 730 visit. The RMP version 8 s2 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.14. Entrectinib - ROZLYTREK (CAP) - EMEA/H/C/004936/X/0017/G

- **Applicant:** Roche Registration GmbH
- **PRAC Rapporteur:** Bianca Mulder

Scope: Grouped application consisting of: 1) Extension application to: a) Introduce a new
pharmaceutical form (coated granules) associated with a new strength (50 mg); b) Introduce a new route of administration (gastroenteral use) for the already authorised 100 mg and 200 mg hard capsules presentations based on final results from studies CO40778 (STARTRK-NG), GO40782 (STARTRK-2) and BO41932 (TAPISTRY). Study CO40778 is a Phase I/II open-label, dose-escalation and expansion study of entrectinib in pediatrics with locally advanced or metastatic solid or primary CNS tumors and/or who have no satisfactory treatment options; Study GO40782 is an open-label, multicenter, global Phase II basket study of entrectinib for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement (fusion), and Study BO41932 is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay; 2) grouped with the following type II variations:

a) to extend the currently approved indication in solid tumours with NTRK gene fusion to patients from birth to 12 years of age (both for the coated granules and already approved hard capsules presentations);

b) to add a new paediatric indication from birth to 18 years of age for patients with solid tumours with a ROS1 gene fusion (both for the coated granules and already approved hard capsules presentations).

As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated accordingly. The package leaflet and Labelling are updated in accordance.

c) to add wording regarding the option of suspension in water of the content of the capsules to be used orally or via the e.g. gastric or nasogastric tube (in sections 4.2 and 5.2 of the SmPC).

The RMP (version 5) is updated in accordance. The MAH took the opportunity to introduce minor editorial changes to the product information and to update Annex II of the SmPC

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.15. Epcoritamab - TEPKINLY (CAP) - EMEA/H/C/005985/II/0001, Orphan

**Applicant:** AbbVie Deutschland GmbH & Co. KG

**PRAC Rapporteur:** Monica Martinez Redondo

**Scope:** Extension of indication to include treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy for TEPKINLY, based on results from the indolent Non-Hodgkin’s Lymphoma (iNHL) expansion cohort of Study GCT3013-01, the First In Human (FIH) Phase 1/2 study in R/R B-NHL, with key supportive data from the Phase 1b/2 Study GCT3013-04 in Japanese subjects. Study GCT3013-01 is an ongoing global, single-arm, phase 1/2 study designed to evaluate epcoritamab as monotherapy in R/R B-NHL. As a consequence, sections 1, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.3, 6.4, 6.5 and 6.6 of the SmPC are updated. The package leaflet and Labelling are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the product information.
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.16. Faricimab - VABYSMO (CAP) - EMEA/H/C/005642/II/0009

**Applicant:** Roche Registration GmbH  
**PRAC Rapporteur:** Carla Torre  
**Scope:** Update of section 4.8 of the SmPC in order to add ‘Retinal Vasculitis’ and ‘Retinal Occlusive Vasculitis’ to the list of adverse drug reactions (ADRs) with frequency not known, based on a drug safety report and post-marketing data; the package leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to add study CR45271 as a category 3 study in the RMP, to introduce minor changes and corrections to the product information and to update the list of local representatives in the package leaflet  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.17. Fedratinib - INREBIC (CAP) - EMEA/H/C/005026/II/0019, Orphan

**Applicant:** Bristol-Myers Squibb Pharma EEIG  
**PRAC Rapporteur:** Sonja Hrabcik  
**Scope:** Update of sections 4.2 and 5.2 of the SmPC in order to update posology recommendations in patients with severe hepatic impairment and to update pharmacokinetic information based on final results from study FEDR-CP-001 listed as a category 3 study in the RMP; this is a phase 1, open-label, single-dose study to assess the pharmacokinetics, safety, and tolerability of fedratinib in subjects with moderate and severe hepatic impairment compared with healthy subjects. The RMP version 2.0 has also been submitted  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.18. Hydroxycarbamide - XROMI (CAP) - EMEA/H/C/004837/II/0019

**Applicant:** Nova Laboratories Ireland Limited  
**PRAC Rapporteur:** Jo Robays  
**Scope:** Extension of indication to include the prevention of vaso-occlusive complications of sickle cell disease in children from 6 months to 2 years of age for Xromi, based on final results from the paediatric study INV543, listed as a category 3 study in the RMP; this is a single-arm, open-label, multi-centre study in children with sickle cell anaemia over 6 months of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.19. Isatuximab - SARCLISA (CAP) - EMEA/H/C/004977/II/0026

**Applicant:** Sanofi Winthrop Industrie
PRAC Rapporteur: Monica Martinez Redondo

Scope: Update of sections 4.2, 4.4 and 5.2 of the SmPC based on final results from study TED16414, listed as a category 3 study in the RMP; this is a phase 1b/2 open label, non-randomised, multi center study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation. The package leaflet is updated accordingly. The RMP version 1.4 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/WS2551/0043; Ivacaftor - KALYDECO (CAP) - EMEA/H/C/002494/WS2551/0121

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Martin Huber

Scope: Extension of the indication for Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) in a combination regimen to include the treatment of patients with cystic fibrosis (CF) aged 2 years and older who do not carry any F508del mutations and have at least one ivacaftor/tezacaftor/elexacaftor-responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene based on study VX21-445-124, study VX21-445-125 and study VX22-CFD-016. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the Kaftrio SmPC are updated; sections 4.1 and 5.1 of the Kalydeco SmPC are updated. The package leaflet is updated in accordance. In addition, the MAH took this opportunity to introduce editorial changes to the product information.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Lenvatinib - KISPLYX (CAP) - EMEA/H/C/004224/WS2631/0059; LENVIMA (CAP) - EMEA/H/C/003727/WS2631/0054

Applicant: Eisai GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC for Kisplyx and sections 4.8 and 5.1 of the SmPC for Lenvima, in order to reflect the results of two completed paediatric clinical studies E7080-G000-216 and E7080-G000-231. Study 231 is a Phase 2, open-label, multicenter basket study to evaluate the antitumor activity and safety of Lenvatinib in children, adolescents, and young adults with relapsed or refractory solid malignancies. Study 216 is a Phase 1/2, multicentre, open-label, single arm study of lenvatinib in combination with everolimus in paediatric subjects (and young adults aged ≤21 years) with relapsed or refractory malignant solid tumors. The package leaflet for Kisplyx is updated accordingly. The RMP version 15.3 has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/II/0021, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Jo Robays

Scope: Extension of indication to include treatment of adult patients with anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS), who may require RBC transfusions for Reblozyl, based on results from study ACE-536-MDS-002 (COMMANDS), an active-controlled, open-label, randomised phase 3 study comparing the efficacy and safety of luspatercept vs epoetin alfa in adult subjects with anaemia due to IPSS-R very low, low or intermediate risk MDS, who are ESA naïve and require RBC transfusions, and studies ACE-536-MDS-001(MEDALIST), ACE-536-MDS-004, A536-03, A536-05 and ACE-536-LTFU-001. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Macitentan - OPSUMIT (CAP) - EMEA/H/C/002697/X/0051/G

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Extension application to introduce a new pharmaceutical form associated with new strengths (1 and 2.5 mg dispersible tablet) grouped with an extension of indication (C.I.6.a) to include, as monotherapy or in combination, the long-term treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 1 month to less than 18 years of age of WHO Functional Class (FC) I to III for OPSUMIT, based on interim results from AC-055-312 study (TOMORROW). This is a multicentre, open-label, randomised study with single-arm extension period to assess the pharmacokinetics, safety, and efficacy of macitentan versus standard of care in children with pulmonary arterial hypertension. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC for film-coated tablets are updated. The package leaflet and Labelling are updated in accordance. Version 14.1 of the RMP has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Mirabegron - BETMIGA (CAP) - EMEA/H/C/002388/X/0039/G

Applicant: Astellas Pharma Europe B.V.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Grouped variations consisting of: 1) extension application to introduce a new pharmaceutical form associated with new strength (8 mg/mL prolonged-release granules for oral suspension); 2) extension of indication to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated accordingly.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Nintedanib - OFEV (CAP) - EMEA/H/C/003821/X/0057/G

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Petar Mas
Scope: Extension application to add a new strength of 25 mg hard capsules, grouped with an extension of indication (C.I.6.a) to include treatment of fibrosing interstitial lung diseases (ILDs) in children and adolescents from 6 to 17 years of age for Ofev, following the assessment of procedure X/0052/G, based on final results from study 1199-0337 (a double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nintedanib of variable duration, in children and adolescents (6 to 17 year-old) with clinically significant fibrosing ILD), which is supplemented by the currently ongoing prospective phase III extension trial 1199-0378 (an open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and adolescents with clinically significant fibrosing ILD). The main objective of the study 1199-0337 was to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing ILD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and Labelling are updated in accordance. Version 12.0 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

**5.3.26. Nirsevimab - BEYFORTUS (CAP) - EMEA/H/C/005304/II/0018/G**

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Kimmo Jaakkola

Scope: Grouped application comprising two type II variations as follows:

C.I.13: Submission of the final report from study D5290C00004 (MELODY) listed as a category 3 study in the RMP. This is a phase III, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of MEDI8897, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants.

C.I.13: Submission of the final report from study D5290C00005 (MEDLEY) listed as a category 3 study in the RMP. This is a phase II/III study, randomised, double-blind, placebo-controlled study to evaluate the safety of Beyfortus (nirsevimab) in high-risk children. The RMP version 2.3 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

**5.3.27. Patisiran - ONPATTRO (CAP) - EMEA/H/C/004699/II/0034, Orphan**

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of the final report from study ALN-TTR02-006 (study 006), listed a category 3 study in the RMP. This is a multicentre, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial amyloidotic polyneuropathy who have completed a prior clinical study with patisiran. The RMP version 2.2 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.28. Peginterferon alfa-2a - PEGASYS (CAP) - EMEA/H/C/000395/II/0119/G

Applicant: Pharmaand GmbH
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Grouped application consisting of extension of indication to include treatment of polycythaemia vera (PV) and essential thrombocytopenia (ET) for PEGASYS, based on published data of clinical studies conducted in support of the efficacy and safety of Pegasys for the treatment of ET and PV. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. Furthermore, the product information is brought in line with the latest QRD template version 10.3
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Sotrovimab - XEVUDY (CAP) - EMEA/H/C/005676/II/0026

Applicant: Glaxosmithkline Trading Services Limited
PRAC Rapporteur: Liana Martirosyan
Scope: To update sections 4.2, 4.8 and 5.2 of the SmPC in order to update information on paediatric population based on final results from study COMET-PACE (215226), a category 3 study in the RMP; this is an open-label, non-comparator, multicentre study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in paediatric participants with mild to moderate COVID-19 at high risk of disease progression. The updated RMP version 1.1 has also been submitted
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Teriflunomide - TERIFLUNOMIDE ACCORD (CAP) - EMEA/H/C/005960/X/0002

Applicant: Accord Healthcare S.L.U.
PRAC Rapporteur: Martin Huber
Scope: Extension application to add a new strength of 7 mg film-coated tablets. The bioequivalence study data were submitted
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/004090/II/0075, Orphan

Applicant: Novartis Europharm Limited, ATMP
PRAC Rapporteur: Gabriele Maurer
Scope: Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTL019C2201 PAES in the Annex II (ANX008); this is a phase II, single arm, multicentre trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The RMP version 6 has also been submitted. In addition, the MAH took the opportunity to update Annex II.D of the product information
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Aclidinium bromide - BRETARIS GENUAIR (CAP); EKLIRA GENUAIR (CAP) - PSUSA/00009005/202307

Applicant: Covis Pharma Europe B.V.
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.2. Ambrisentan - VOLIBRIS (CAP) - PSUSA/00000129/202306

Applicant: GlaxoSmithKline (Ireland) Limited
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.3. Asfotase alfa - STRENSIQ (CAP) - PSUSA/00010421/202307

Applicant: Alexion Europe SAS
PRAC Rapporteur: Eamon O’Murchu
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.4. Avanafil - SPEDRA (CAP) - PSUSA/00010066/202306

Applicant: Menarini International Operations Luxembourg S.A.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.5. Avapritinib - AYVAKYT (CAP) - PSUSA/00010878/202307

Applicant: Blueprint Medicines (Netherlands) B.V.
6.1.6. **Beclometasone, formoterol, glycopyrronium bromide - RIARIFY (CAP); TRIMBOW (CAP); TRYDONIS (CAP) - PSUSA/00010617/202307**

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.1.7. **Birch bark extract \(^9\) - FILSUVEZ (CAP) - PSUSA/00010446/202307**

Applicant: Amryt Pharmaceuticals DAC

PRAC Rapporteur: Zane Neikena

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.1.8. **Brexicabtagene autoleucel - TECARTUS (CAP) - PSUSA/00010903/202307**

Applicant: Kite Pharma EU B.V., ATMP

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CAT and CHMP

---

6.1.9. **Budesonide\(^10\) - JORVEZA (CAP) - PSUSA/00010664/202307**

Applicant: Dr. Falk Pharma GmbH

PRAC Rapporteur: Zane Neikena

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.1.10. **Carfilzomib - KYPROLIS (CAP) - PSUSA/00010448/202307**

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Petar Mas

Scope: Evaluation of a PSUSA procedure

---

\(^9\) Centrally authorised product(s) only

\(^10\) For centrally authorised product(s) indicated for eosinophilic esophagitis only
**Action:** For adoption of recommendation to CHMP

### 6.1.11. Casirivimab, imdevimab - RONAPREVE (CAP) - PSUSA/00010963/202307

Applicant: Roche Registration GmbH  
PRAC Rapporteur: Ulla Wändel Liminga  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.12. Cenegermin - OXERVATE (CAP) - PSUSA/00010624/202307

Applicant: Dompe farmaceutici S.p.A.  
PRAC Rapporteur: Jan Neuhauser  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.13. Cladribine\(^\text{11}\) - MAVENCLAD (CAP) - PSUSA/00010634/202307

Applicant: Merck Europe B.V.  
PRAC Rapporteur: Carla Torre  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP


Applicant: Idorsia Pharmaceuticals Deutschland GmbH  
PRAC Rapporteur: Ana Sofia Diniz Martins  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.15. Eptacog beta (activated) - CEVENFACTA (CAP) - PSUSA/00011006/202307

Applicant: Laboratoire Francais du Fractionnement et des Biotechnologies  
PRAC Rapporteur: Bianca Mulder  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

\(^{11}\) Multiple sclerosis indication only
<table>
<thead>
<tr>
<th>6.1.16.</th>
<th>Faricimab - VABYSMO (CAP) - PSUSA/00011016/202307</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant: Roche Registration GmbH</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Carla Torre</td>
<td></td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.17.</th>
<th>Finerenone - KERENDIA (CAP) - PSUSA/00010978/202307</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant: Bayer AG</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Bianca Mulder</td>
<td></td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.18.</th>
<th>Glucagon(^{12}) - BAQSIMI (CAP); OGLUO (CAP) - PSUSA/00010826/202307</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant: Eli Lilly Nederland B.V. (BAQSIMI), Tetris Pharma B.V. (Ogluo)</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Eamon O’Murchu</td>
<td></td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant: SERB S.A.S.</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Martin Huber</td>
<td></td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.20.</th>
<th>Guselkumab - TREMFYA (CAP) - PSUSA/00010652/202307</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant: Janssen-Cilag International N.V.</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Gabriele Maurer</td>
<td></td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
<td></td>
</tr>
<tr>
<td><strong>Action</strong>: For adoption of recommendation to CHMP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6.1.21.</th>
<th>Human C1-esterase inhibitor - CINRYZE (CAP) - PSUSA/00010104/202306</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant: Takeda Manufacturing Austria AG</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Gabriele Maurer</td>
<td></td>
</tr>
</tbody>
</table>

\(^{12}\) For centrally authorised product(s) only
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.22. Icosapent ethyl - VAZKEPA (CAP) - PSUSA/00010922/202307

Applicant: Amarin Pharmaceuticals Ireland Limited

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.23. Imipenem, cilastatin, relebactam - RECARBRIO (CAP) - PSUSA/00010830/202307

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.24. Indacaterol, glycopyrronium, mometasone - ENERZAIR BREEZHALER (CAP); ZIMBUS BREEZHALER (CAP) - PSUSA/00010861/202307

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.25. Inotersen - TEGSEDI (CAP) - PSUSA/00010697/202307

Applicant: Akcea Therapeutics Ireland Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.26. L-lysine hydrochloride, l-arginine hydrochloride - LYSAKARE (CAP) - PSUSA/00010786/202307

Applicant: Advanced Accelerator Applications

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP
6.1.27. **Neratinib - NERLYNX (CAP) - PSUSA/00010712/202307**

- **Applicant:** Pierre Fabre Medicament
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

6.1.28. **Nirmatrelvir, ritonavir - PAXLOVID (CAP) - PSUSA/00010984/202306**

- **Applicant:** Pfizer Europe MA EEIG
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

6.1.29. **Nonacog gamma - RIXUBIS (CAP) - PSUSA/00010320/202306**

- **Applicant:** Baxalta Innovations GmbH
- **PRAC Rapporteur:** Gabriele Maurer
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

6.1.30. **Odevixibat - BYLVAY (CAP) - PSUSA/00010949/202307**

- **Applicant:** Albireo
- **PRAC Rapporteur:** Adam Przybylkowski
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

6.1.31. **Peginterferon alfa-2a - PEGASYS (CAP) - PSUSA/00009254/202307**

- **Applicant:** Pharmaand GmbH
- **PRAC Rapporteur:** Ulla Wändel Liminga
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

6.1.32. **Pneumococcal polysaccharide conjugate vaccine (15 valent, adsorbed) - VAXNEUVANCE (CAP) - PSUSA/00010975/202307**

- **Applicant:** Merck Sharp & Dohme B.V.
- **PRAC Rapporteur:** Gabriele Maurer
- **Scope:** Evaluation of a PSUSA procedure
**Action**: For adoption of recommendation to CHMP

### 6.1.33. Relugolix - ORGOVYX (CAP) - PSUSA/00010994/202307

- **Applicant**: Accord Healthcare S.L.U.
- **PRAC Rapporteur**: Karin Erneholm
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.34. Remimazolam - BYFAVO (CAP) - PSUSA/00010924/202307

- **Applicant**: Paion Deutschland GmbH
- **PRAC Rapporteur**: Eamon O Murchu
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.35. Spheroids of human autologous matrix-associated chondrocytes - SPHEROX (CAP) - PSUSA/00010630/202307

- **Applicant**: Co.Don GmbH, ATMP
- **PRAC Rapporteur**: Gabriele Maurer
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CAT and CHMP

### 6.1.36. Tasimelteon - HETLIOZ (CAP) - PSUSA/00010394/202307

- **Applicant**: Vanda Pharmaceuticals Netherlands B.V.
- **PRAC Rapporteur**: Adam Przybylkowski
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.37. Tebentafusp - KIMMTRAK (CAP) - PSUSA/00010991/202307

- **Applicant**: Immunocore Ireland Limited
- **PRAC Rapporteur**: Bianca Mulder
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.38. Tecovirimat - TECOHIRMAT SIGA (CAP) - PSUSA/00010971/202307

- **Applicant**: SIGA Technologies Netherlands B.V.
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.39. Tedizolid phosphate - SIVEXTRO (CAP) - PSUSA/00010369/202306

Applicant: Merck Sharp & Dohme B.V.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.40. Tigecycline - TYGACIL (CAP) - PSUSA/00002954/202306

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.41. Vericiguat - VERQUVO (CAP) - PSUSA/00010950/202307

Applicant: Bayer AG
PRAC Rapporteur: Kimmo Jaakkola
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.42. Voclosporin - LUPKYNIS (CAP) - PSUSA/00011020/202307

Applicant: Otsuka Pharmaceutical Netherlands B.V.
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.43. Voretigene neparvovec - LUXTURNA (CAP) - PSUSA/00010742/202307

Applicant: Novartis Europharm Limited, ATMP
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CAT and CHMP
6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

6.2.1. **Caffeine** - GENCEBOK (CAP); PEYONA (CAP); NAP - PSUSA/00000482/202307

Applicant: Gennisium Pharma (Gencebok), Chiesi Farmaceutici S.p.A. (Peyona), various
PRAC Rapporteur: Sonja Hrabcik
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. **Acetylsalicylic acid, rosvastatin (NAP) - PSUSA/00010893/202306**

Applicant(s): various
PRAC Lead: Polona Golmajer
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.2. **Allergen for therapy: betula verrucosa** - PSUSA/00010815/202307

Applicant(s): various
PRAC Lead: Kirsti Villikka
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.3. **Almotriptan (NAP) - PSUSA/00000101/202306**

Applicant(s): various
PRAC Lead: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.4. **Cyproterone (NAP) - PSUSA/00000905/202307**

Applicant(s): various
PRAC Lead: Petar Mas

---

13 Apnea indication only
14 Sublingual use only
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.5. Diclofenac, misoprostol (NAP) - PSUSA/00001040/202307

Applicant(s): various

PRAC Lead: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.6. Epirubicin (NAP) - PSUSA/00001234/202306

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.7. Ferucarbotran (NAP) - PSUSA/00001382/202306

Applicant(s): various

PRAC Lead: Mari Thörn

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.8. Hepatitis A (inactivated), typhoid polysaccharide vaccine (adsorbed) (NAP) - PSUSA/00001594/202306

Applicant(s): various

PRAC Lead: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.9. Ibuprofen, pseudoephedrine (NAP) - PSUSA/00001711/202307

Applicant(s): various

PRAC Lead: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh
6.3.10. **Levocetirizine (NAP) - PSUSA/00001850/202307**

Applicant(s): various
PRAC Lead: Martin Huber
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.11. **Misoprostol\(^\text{15}\) (NAP) - PSUSA/00010291/202306**

Applicant(s): various
PRAC Lead: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.12. **Nimesulide\(^\text{16}\) (NAP) - PSUSA/00002165/202306**

Applicant(s): various
PRAC Lead: Amelia Cupelli
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.13. **Octreotide (NAP) - PSUSA/00002201/202306**

Applicant(s): various
PRAC Lead: Eamon O'Murchu
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.14. **Oxycodone hydrochloride, paracetamol (NAP) - PSUSA/00002256/202307**

Applicant(s): various
PRAC Lead: Amelia Cupelli
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.15. **Oxytocin\(^\text{17}\) (NAP) - PSUSA/00010913/202306**

Applicant(s): various

---

\(^{15}\) Gastrointestinal indication only
\(^{16}\) Topical formulation(s) only
\(^{17}\) Systemic use only
6.3.16. **Oxytocin\(^{18}\) (NAP) - PSUSA/00010914/202306**

Applicant(s): various
PRAC Lead: Karen Pernille Harg
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

---

6.3.17. **Paracetamol, pseudoephedrine (NAP) - PSUSA/00002307/202306**

Applicant(s): various
PRAC Lead: Jo Robays
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

---

6.3.18. **Phentermine, topiramate (NAP) - PSUSA/00010956/202307**

Applicant(s): various
PRAC Lead: Mari Thörn
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

---

6.3.19. **Pseudoephedrine (NAP); acetylsalicylic acid, pseudoephedrine (NAP) - PSUSA/00010667/202306**

Applicant(s): various
PRAC Lead: Maia Uusküla
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

---

6.3.20. **Rizatriptan (NAP) - PSUSA/00002655/202306**

Applicant(s): various
PRAC Lead: Liana Martirosyan
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

---

\(^{18}\) Nasal spray only
6.3.21. Tramadol (NAP) - PSUSA/00003002/202306

Applicant(s): various
PRAC Lead: Tiphaine Vaillant
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Abatacept - ORENCIA (CAP) - EMEA/H/C/000701/LEG 071

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Kimmo Jaakkola
Scope: From /PSUSA/00000013/202212:
1. updated cumulative review about progressive multifocal leukoencephalopathy (PML), including information from post-marketing cases, clinical trials, real-world data and literature.
2. cumulative review on the association between abatacept and sarcoidosis, including information from post-marketing cases, clinical trials, real world data, and literature
Action: For adoption of advice to CHMP

6.4.2. Piperaquine tetraphosphate, arteminol - EURARTESIM (CAP) - EMEA/H/C/001199/LEG 018.1

Applicant: Alfasigma S.p.A.
PRAC Rapporteur: Martin Huber
Scope: MAH's response to LEG 018 request for supplementary information as adopted in October 2023. In view of the available data regarding “autoimmune haemolytic anaemia” and “delayed haemolytic anaemia” the MAH is requested to propose a wording to update the product information of arteminol / piperaquine tetraphosphate (Eurartesim) with the new information regarding “autoimmune haemolytic anaemia” and “delayed haemolytic anaemia” in section 4.4 and 4.8 of the SmPC and corresponding sections of the PL
Action: For adoption of advice to CHMP

6.4.3. Tocilizumab - ROACTEMRA (CAP) - EMEA/H/C/000955/LEG 063.1

Applicant: Roche Registration GmbH
PRAC Rapporteur: Gabriele Maurer
Scope: MAH's response to LEG 063 [to perform cumulative reviews of reports from clinical trials, post-marketing studies, literature and spontaneous reports concerning (i) psychiatric disorders including depression and related disorders, (ii) ulcerative keratitis, and (iii) pyoderma gangrenosum. To discuss potential pathomechanisms.] as adopted in September 2023

Pharmacovigilance Risk Assessment Committee (PRAC)
EMA/PRAC/11237/2024
**Action:** For adoption of advice to CHMP

### 6.4.4. Vernakalant - BRINAVESS (CAP) - EMEA/H/C/001215/LEG 034

**Applicant:** Correvio  
**PRAC Rapporteur:** Bianca Mulder  
**Scope:** Vernakalant hypotension notification for case number 202311010464:  
To perform a parallel submission of serious special interest case reports associated with Brinavess  
**Action:** For adoption of advice to CHMP

### 6.5. Variation procedure(s) resulting from PSUSA evaluation

#### 6.5.1. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0054, Orphan

**Applicant:** Amgen Europe B.V.  
**PRAC Rapporteur:** Jana Lukacisinova  
**Scope:** To update sections 4.2, 4.4, 4.8 of the SmPC to include immune effector cell-associated neurotoxicity syndrome (ICANS); and to update section D of Annex II to remove educational materials for physicians, pharmacists and nurses and to include ICANS within neurologic events in educational material for patient/caregivers and patient alert card following the outcome of PSUR procedure EMEA/H/C/PSUSA/00010460/202212. The package leaflet is updated accordingly. The RMP version 17.0 has also been submitted  
**Action:** For adoption of PRAC Assessment Report

#### 6.5.2. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/II/0063

**Applicant:** Orexigen Therapeutics Ireland Limited  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Submission of an update of sections 4.3, 4.4 and 4.5 of the SmPC to update and streamline the relevant wording on opioids as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00010366/202209) adopted in April 2023. The package leaflet is updated accordingly. The RMP version 12.9 has also been submitted  
**Action:** For adoption of PRAC Assessment Report

#### 6.5.3. Rituximab - MABTHERA (CAP) - EMEA/H/C/000165/II/0201/G

**Applicant:** Roche Registration GmbH  
**PRAC Rapporteur:** Karin Erneholm  
**Scope:** A grouped application comprising of:  
Type II (C.I.3.b): Update of sections 4.1, 4.2, 4.3, 4.8, 5.1, 6.2, 6.4 and 6.5 of the SmPC in order to introduce several structural and editorial changes to align with the current SmPC
guideline and to remove the educational materials for healthcare professionals (HCPs) and patients, following the request by PRAC in the assessment report for the PSUSA procedure EMA/PRAC/257005/2023. The Annex II, Labelling and package leaflet are updated accordingly. The RMP version 25.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and to update the list of local representatives in the package leaflet.

Type I (A.6): To change the ATC Code of rituximab from L01XC02 to L01FA01

**Action:** For adoption of PRAC Assessment Report

### 6.6. Expedited summary safety reviews

None

### 7. Post-authorisation safety studies (PASS)

#### 7.1. Protocols of PASS imposed in the marketing authorisation(s)

None

#### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)

**7.2.1. Agalsidase beta - FABRAZYME (CAP) - EMEA/H/C/000370/MEA 065**

Applicant: Sanofi B.V.

PRAC Rapporteur: Liana Martirosyan

Scope: EPIDEMIOLOGY STUDY PROTOCOL, study no.: EPM0086 ; Fabrazyme (agalsidase beta) home infusion educational materials effectiveness evaluation: a survey of nurses administering home infusions

**Action:** For adoption of advice to CHMP

**7.2.2. Atogepant - AQUIPTA (CAP) - EMEA/H/C/005871/MEA 002**

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Rugile Pilvinienė

Scope: From Initial MAA: PASS Study Protocol, study no.: P24433 (RMP version 1.0); Title: PASS to evaluate the utilisation and safety of atogepant in patients with migraine and significant cardiovascular or cerebrovascular disease in Europe

**Action:** For adoption of advice to CHMP

---

19 Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

20 In accordance with Article 107m of Directive 2001/83/EC

21 In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
7.2.3. Birch bark extract - FILSUVEZ (CAP) - EMEA/H/C/005035/MEA 001.2

Applicant: Amryt Pharmaceuticals DAC

PRAC Rapporteur: Zane Neikena

Scope: REVISED PROTOCOL / [PASS (FOSTER-EB) [(AEB-21)]; Observational safety and effectiveness evaluation registry-based study in Epidermolysis Bullosa (EB) (FOSTER-EB) [(AEB-21)] to evaluate the long-term safety of Filsuvez amongst patients treated for EB in relation to the incidence, severity and relatedness of skin malignancies (including squamous cell carcinoma, basal cell carcinoma and malignant melanoma, and use in patients with different skin types regarding ethnic origin

Action: For adoption of advice to CHMP

7.2.4. Cinacalcet - MIMPARA (CAP) - EMEA/H/C/000570/MEA 035.8

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: Protocol amendment for the observational registry study (20180204) to evaluate the risk of hypocalcaemia (e.g., clinical characteristics, laboratory variables [PTH, Ca, and P], hospitalisation due to hypocalcaemia, co-medication, cinacalcet doses) in paediatric patients treated with cinacalcet

Action: For adoption of advice to CHMP

7.2.5. Coronavirus (COVID-19) vaccine (B.1.351 variant, prefusion Spike delta TM protein, recombinant) - VIDPREVTYN BETA (CAP) - EMEA/H/C/005754/MEA 002.3

Applicant: Sanofi Pasteur

PRAC Rapporteur: Jana Lukacinova

Scope: MAH's response to MEA 002.2 [Revised PASS Protocol / Study number: VAT 00007] RSI as adopted in October 2023. REAL WORLD AND EPIDEMIOLOGY STUDY PROTOCOL; Title: Post-authorisation, observational study to assess the safety of VidPrevtyn Beta using routinely collected secondary data in Europe through VAC4EU. A non-interventional PASS to assess the occurrence of pre-specified AESIs and safety concerns following administration of VidPrevtyn Beta as a booster dose in a real-world setting

Action: For adoption of advice to CHMP

7.2.6. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/MEA 012.1

Applicant: Roche Registration GmbH

PRAC Rapporteur: Amelia Cupelli


Action: For adoption of advice to CHMP
7.2.7. **Enfortumab vedotin - PADCEV (CAP) - EMEA/H/C/005392/MEA 003.1**

**Applicant:** Astellas Pharma Europe B.V.
**PRAC Rapporteur:** Eva Jirsová

**Scope:** Updated Study Protocol / Study no.: 7465-PV-0002 version 2.0; To evaluate patients understanding and awareness of the content of the patient card related to risks of skin reactions and patients behaviours to minimise the risks

**Action:** For adoption of advice to CHMP

7.2.8. **Filgotinib - JYSELECA (CAP) - EMEA/H/C/005113/MEA 017.1**

**Applicant:** Galapagos N.V.
**PRAC Rapporteur:** Petar Mas

**Scope:** MAH’s response to MEA 017 [Protocol for study GLPG0634-CL-417: non-interventional, post-authorisation, cohort, safety study evaluating the effectiveness of the additional risk minimization measures for filgotinib (Jyseleca) use in patients with moderately to severely active ulcerative colitis within multiple European registries] as per the request for supplementary information (RSI) as adopted in September 2023

**Action:** For adoption of advice to CHMP

7.2.9. **Linzagolix choline - YSELTY (CAP) - EMEA/H/C/005442/MEA 002.2**

**Applicant:** Theramex Ireland Limited
**PRAC Rapporteur:** Martin Huber

**Scope:** MAH’s response to MEA 002.1 as per request for supplementary information adopted in October 2023 together with an updated protocol for study YSELTY PASS: A multinational PASS on real-world treatment in patients receiving YSELTY (linzagolix choline) for moderate to severe symptoms of uterine fibroids, to evaluate routinely collected data on bone mineral density and to assess safety during long term (>12 months) use for linzagolix 200mg (with ABT) and 100mg (with and without ABT) dosing regimen

**Action:** For adoption of advice to CHMP

7.2.10. **Mirikizumab - OMVOH (CAP) - EMEA/H/C/005122/MEA 001**

**Applicant:** Eli Lilly Nederland B.V.
**PRAC Rapporteur:** Sonja Hrabcik

**Scope:** From initial MAA: Protocol / I6T-MC-B003; Observational Study of Pregnancy and Infant Outcomes Among Women Exposed to Mirikizumab During Pregnancy in US-based Administrative Claims Data

**Action:** For adoption of advice to CHMP
7.2.11.  **Mirikizumab - OMVOH (CAP) - EMEA/H/C/005122/MEA 002**

Applicant: Eli Lilly Nederland B.V.
PRAC Rapporteur: Sonja Hrabcik
Scope: From initial MAA: Protocol / I6T-MC-B004; Observational Secondary Database Study to Assess the Long-Term Safety of Mirikizumab in Routine Clinical Practice Using US Administrative Claims Data

**Action:** For adoption of advice to CHMP

7.2.12.  **Naldemedine - RIZMOIC (CAP) - EMEA/H/C/004256/MEA 001.6**

Applicant: Shionogi B.V.
PRAC Rapporteur: Eamon O Murchu
Scope: MAH's response to MEA 001.5 for an Observational PASS of Patients with Chronic Opioid Use for Non-Cancer and Cancer Pain who have Opioid-Induced Constipation (OIC) as per the request for supplementary information adopted in October 2023

**Action:** For adoption of advice to CHMP

7.2.13.  **Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/MEA 005.7**

Applicant: BioMarin International Limited
PRAC Rapporteur: Rhea Fitzgerald
Scope: Protocol Amendment 4 for study 165-504: A global, multicenter study to assess maternal, fetal and infant outcomes of exposure to Palynziq (pegvaliase) during pregnancy and breastfeeding

**Action:** For adoption of advice to CHMP

7.2.14.  **Pitolisant - OZAWADE (CAP) - EMEA/H/C/005117/MEA 003.2**

Applicant: Bioprojet Pharma
PRAC Rapporteur: Kirsti Villikka
Scope: Revised Protocol / Study no.: P21-02; A multi-centre, observational prospective PASS to compare the cardiovascular risks and long-term safety of OZAWADE in patients with obstructive sleep apnoea treated or not by primary therapy and exposed or not to OZAWADE when used in routine medical practice

**Action:** For adoption of advice to CHMP

7.2.15.  **Respiratory syncytial virus vaccine (bivalent, recombinant) - ABRYSVO (CAP) - EMEA/H/C/006027/MEA 002.1**

Applicant: Pfizer Europe Ma EEIG
PRAC Rapporteur: Liana Martirosyan
Scope: Revised Protocol, Study C3671031; Title: A Post-Authorization Safety Study of
Guillain-Barré Syndrome (GBS) Following ABRYSVOTM Among Older Adults in the United States. (v.1.0)

7.3. Results of PASS imposed in the marketing authorisation(s)\textsuperscript{22}

None

7.4. Results of PASS non-imposed in the marketing authorisation(s)\textsuperscript{23}

7.4.1. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/WS2587/0085; Diroximel fumarate - VUMERITY (CAP) - EMEA/H/C/005437/WS2587/0015

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Submission of the final report from study 109MS401, a multicentre, global, observational study to collect information on safety and to document the drug utilisation of Tecfidera (Dimethyl Fumarate) when used in routine medical practice in the treatment of Multiple Sclerosis (ESTEEM), listed as a category 3 study in the RMP (MEA007.6). The RMPs version 16.1 for Tecfidera and version 2.1 for Vumerity, have also been submitted.

Action: For adoption of PRAC Assessment Report

7.4.2. Dolutegravir, lamivudine - DOVATO (CAP) - EMEA/H/C/004909/WS2620/0047; Dolutegravir, Rilpivirine - JULUCA (CAP) - EMEA/H/C/004427/WS2620/0056; Dolutegravir - TIVICAY (CAP) - EMEA/H/C/002753/WS2620/0092; Dolutegravir, Abacavir, Lamivudine - TRIUMEQ (CAP) - EMEA/H/C/002754/WS2620/0118

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.6 of the SmPC in order to update information about the use of dolutegravir (DTG)-containing regimens in pregnancy and at conception based on final results from non-interventional Tsepamo study and the Eswatini Birth Outcomes Surveillance study. In addition, data from other cohort studies and pregnancy registries, including the Antiretroviral Pregnancy Registry (APR), DOLOMITE-EPPICC (Study 208613) and DOLOMITE-NEAT-ID Network study (Study 208759) both listed as category 3 studies in the RMP; and the US Chart Review (Study 212976) as well as data from literature are included. DOLOMITE-EPPICC (Study 208613) is a non-interventional study to Assess "real-world" maternal and foetal outcomes following DTG use during pregnancy and to describe patterns of DTG utilization; DOLOMITE NEAT ID Network Study (208759) is a non-interventional, multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women. The package leaflet is updated accordingly. The RMP version 19 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to sections 4.4 and 4.5 of the SmPC.

\textsuperscript{22} In accordance with Article 107p-q of Directive 2001/83/EC

\textsuperscript{23} In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
Action: For adoption of PRAC Assessment Report

7.4.3.  Epoetin alfa - ABSEAMED (CAP) - EMEA/H/C/000727/WS2615/0108;  
Epoetin alfa - BINOCRIT (CAP) - EMEA/H/C/000725/WS2615/0108;  
Epoetin alfa - EPOETIN ALFA HEXAL (CAP) - EMEA/H/C/000726/WS2615/0108

Applicant: Sandoz GmbH  
PRAC Rapporteur: Tiphaine Vaillant  
Scope: Submission of the final report from Non-Interventional PASS, NI-PASS HX575-507 listed as a category 3 study in the RMP. The non-interventional study (NIS PASS) study HX575-507 was conducted to address a post-approval requirement (MEA 13.5) to evaluate the safety profile of HX575 administered s.c. in patients with CKD-induced anemia under real-life conditions, in order to increase confidence on the safe use of s.c. HX575. The RMP version 19.0 has also been submitted  
Action: For adoption of PRAC Assessment Report

7.4.4.  Hepatitis B surface antigen (rDNA) - HEPLISAV B (CAP) -  
EMEA/H/C/005063/II/0031

Applicant: Dynavax GmbH  
PRAC Rapporteur: Gabriele Maurer  
Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy based on final results from study DV2-HBV-28 - Post-marketing observational surveillance study to evaluate pregnancy outcomes among women who receive HEPLISAV-B or Engerix-B; HBV-28 was conducted using the same patient population as two observational post-marketing surveillance studies designed to evaluate the incidence of AMI (HBV-25) or new-onset immune-mediated diseases, herpes zoster, and anaphylaxis (HBV-26) in recipients of HEPLISAV-B compared with recipients of Engerix-B. The primary objective of this study was to describe and compare pregnancy outcomes in recipients of HEPLISAV-B and recipients of Engerix-B. The package leaflet is updated accordingly. The RMP version 1.4 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3  
Action: For adoption of PRAC Assessment Report

7.4.5.  Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/II/0101/G

Applicant: Janssen-Cilag International N.V.  
PRAC Rapporteur: Rhea Fitzgerald  
Scope: Update of section 4.4 of the SmPC in order to remove a warning on cardiovascular events based on final results from non-interventional PASS studies NDI-MACE (CNT01275PSO4005) and Quantify MACE (PCSIMM004697), listed as category 3 studies in the RMP (MEA/053 and MEA/054). NDI-MACE is a Nordic database initiative for exposure to ustekinumab: a review and analysis of major adverse cardiovascular events (MACE) from the Swedish and Danish national registry systems; Quantify MACE is an observational longitudinal PASS of STELARA in the treatment of psoriasis and psoriatic arthritis: analysis of major adverse cardiovascular events (MACE) using Swedish national health registers. The
package leaflet is updated accordingly. The RMP version 27.1 has also been submitted

**Action:** For adoption of PRAC Assessment Report

### 7.4.6. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/II/0081

**Applicant:** Takeda Pharma A/S

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** Update of section 4.6 of the SmPC in order to update information on pregnancy based on final results from study Vedolizumab-5001 (OTIS Entyvio Pregnancy Exposure Registry); this is a non-interventional study to monitor planned and unplanned pregnancies in female patients with ulcerative colitis or Crohn’s disease. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes and corrections to the product information and bring it in line with the latest QRD template

**Action:** For adoption of PRAC Assessment Report

### 7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

#### 7.5.1. Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/MEA 007.5

**Applicant:** Akcea Therapeutics Ireland Limited

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** Interim study report for PASS No TG4005 (non-imposed/non-interventional); Pregnancy surveillance program of women and infants exposed to Tegsedi during pregnancy

**Action:** For adoption of advice to CHMP

#### 7.5.2. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/MEA 006.15

**Applicant:** Kyowa Kirin Holdings B.V.

**PRAC Rapporteur:** Eamon O Murchu

**Scope:** MAH’s response to MEA 006.14 [Final progress report for study D3820R00009 - Naloxegol Health Outcomes PASS – An observational PASS of MOVENTIG (Naloxegol) Among Patients Aged 18 Years and Older Diagnosed with Non-Cancer Pain and Cancer Pain and Treated with Opioids Chronically in Selected European Populations] as per the request for supplementary information (RSI) adopted in September 2023

**Action:** For adoption of advice to CHMP

#### 7.5.3. Risdiplam - EVRYSDI (CAP) - EMEA/H/C/005145/MEA 007.4

**Applicant:** Roche Registration GmbH

**PRAC Rapporteur:** Jan Neuhauser

**Scope:** Second interim study report for study BN42833 (Risdiplam Pregnancy Surveillance
Study): A Phase IV, non-interventional surveillance study

**Action:** For adoption of advice to CHMP

### 7.5.4. Rivaroxaban - XARELTO (CAP) - EMEA/H/C/000944/MEA 049.4

**Applicant:** Bayer AG

**PRAC Rapporteur:** Mari Thorn

**Scope:** First progress report for the Xarelto Paediatric VTE PASS Drug Utilization Study: an observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (XAPAEDUS)

**Action:** For adoption of advice to CHMP

### 7.5.5. Siponimod - MAYZENT (CAP) - EMEA/H/C/004712/MEA 004.4

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Maria del Pilar Rayon

**Scope:** MAH’s response to MEA 004.3 [Interim study report for the survey among healthcare professionals and MS patients/caregivers (study CBAF312A2006)] as per request for supplementary information adopted in October 2023

**Action:** For adoption of advice to CHMP

### 7.5.6. Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/MEA 032.4

**Applicant:** Astellas Pharma Europe B.V.

**PRAC Rapporteur:** Eamon O Murchu

**Scope:** Progress Report / Study No.: 2868371 v.1.0; Feasibility assessment of conducting a NI-PASS of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from available secondary use data sources to replicate the Transplant Pregnancy Registry International (TPRI) study

**Action:** For adoption of advice to CHMP

### 7.5.7. Tacrolimus - MODIGRAF (CAP) - EMEA/H/C/000954/MEA 024.4

**Applicant:** Astellas Pharma Europe B.V.

**PRAC Rapporteur:** Mari Thorn

**Scope:** Progress Report / Study No.: 2868371 v.1.0; Feasibility assessment of conducting a NI-PASS of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from available secondary use data sources to replicate the Transplant Pregnancy Registry International (TPRI) study

**Action:** For adoption of advice to CHMP
7.5.8. **Teduglutide - REVESTIVE (CAP) - EMEA/H/C/002345/ANX 003.11**

Applicant: Takeda Pharmaceuticals International AG Ireland Branch  
PRAC Rapporteur: Marie Louise Schougaard Christiansen  
Scope: MAH Response to ANX 003.10 [Fourth interim report for study TED-R-13-002: an international short bowel syndrome registry - a prospective, long-term observational cohort study of patients with short bowel syndrome] as adopted in October 2023  
**Action:** For adoption of advice to CHMP

7.6. **Others**

None

7.7. **New Scientific Advice**

None

7.8. **Ongoing Scientific Advice**

None

7.9. **Final Scientific Advice (Reports and Scientific Advice letters)**

None

8. **Renewals of the marketing authorisation, conditional renewal and annual reassessments**

8.1. **Annual reassessments of the marketing authorisation**

8.1.1. **Cholic acid - ORPHACOL (CAP) - EMEA/H/C/001250/S/0053 (without RMP)**

Applicant: Theravia  
PRAC Rapporteur: Sofia Trantza  
Scope: Annual reassessment of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.1.2. **Eladocagene exuparvovec - UPSTAZA (CAP) - EMEA/H/C/005352/S/0017 (without RMP)**

Applicant: PTC Therapeutics International Limited, ATMP  
PRAC Rapporteur: Gabriele Maurer
Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CAT and CHMP

### 8.1.3. Fosdenopterin - NULIBRY (CAP) - EMEA/H/C/005378/S/0006 (without RMP)

- **Applicant:** TMC Pharma (EU) Limited
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Annual reassessment of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.1.4. Idebenone - RAXONE (CAP) - EMEA/H/C/003834/S/0035 (without RMP)

- **Applicant:** Chiesi Farmaceutici S.p.A.
- **PRAC Rapporteur:** Amelia Cupelli
- **Scope:** Annual reassessment of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.1.5. Lomitapide - LOJUXTA (CAP) - EMEA/H/C/002578/S/0057 (without RMP)

- **Applicant:** Amryt Pharmaceuticals DAC
- **PRAC Rapporteur:** Bianca Mulder
- **Scope:** Annual reassessment of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.1.6. Obiltoxaximab - NYXTHRACIS (CAP) - EMEA/H/C/005169/S/0013 (without RMP)

- **Applicant:** SFL Pharmaceuticals Deutschland GmbH
- **PRAC Rapporteur:** Liana Martirosyan
- **Scope:** Annual reassessment of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.1.7. Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) - EMEA/H/C/002596/S/0095 (without RMP)

- **Applicant:** Bavarian Nordic A/S
- **PRAC Rapporteur:** Gabriele Maurer
- **Scope:** Annual reassessment of the marketing authorisation
- **Action:** For adoption of advice to CHMP
8.1.8. **Tocofersolan - VEDROP (CAP) - EMEA/H/C/000920/S/0049 (without RMP)**

Applicant: Recordati Rare Diseases  
PRAC Rapporteur: Melinda Palfi  
Scope: Annual reassessment of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.2. **Conditional renewals of the marketing authorisation**

8.2.1. **Mosunetuzumab - LUNSUMIO (CAP) - EMEA/H/C/005680/R/0008 (without RMP)**

Applicant: Roche Registration GmbH  
PRAC Rapporteur: Ulla Wändel Liminga  
Scope: Conditional renewal of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.2.2. **Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - PANDEMIC INFLUENZA VACCINE H5N1 ASTRazeneca (CAP) - EMEA/H/C/003963/R/0071 (without RMP)**

Applicant: AstraZeneca AB  
PRAC Rapporteur: Sonja Hrabcik  
Scope: Conditional renewal of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.2.3. **Selumetinib - KOSELUGO (CAP) - EMEA/H/C/005244/R/0015 (without RMP)**

Applicant: AstraZeneca AB  
PRAC Rapporteur: Ulla Wändel Liminga  
Scope: Conditional renewal of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.3. **Renewals of the marketing authorisation**

8.3.1. **Idelalisib - ZYDELIG (CAP) - EMEA/H/C/003843/R/0059 (with RMP)**

Applicant: Gilead Sciences Ireland UC  
PRAC Rapporteur: Martin Huber  
Scope: 5-year renewal of the marketing authorisation  
**Action:** For adoption of advice to CHMP
8.3.2. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/R/0020 (without RMP)

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.3. L-lysine hydrochloride, l-arginine hydrochloride - LYSAKARE (CAP) - EMEA/H/C/004541/R/0016 (without RMP)

Applicant: Advanced Accelerator Applications
PRAC Rapporteur: Adam Przybylkowski
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.4. Pegfilgrastim - GRASUSTEK (CAP) - EMEA/H/C/004556/R/0014 (with RMP)

Applicant: Juta Pharma GmbH
PRAC Rapporteur: Bianca Mulder
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.5. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/R/0038 (without RMP)

Applicant: BioMarin International Limited
PRAC Rapporteur: Rhea Fitzgerald
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.6. Posaconazole - POSACONAZOLE ACCORD (CAP) - EMEA/H/C/005005/R/0014 (with RMP)

Applicant: Accord Healthcare S.L.U.
PRAC Rapporteur: Nathalie Gault
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.7. Posaconazole - POSACONAZOLE AHCL (CAP) - EMEA/H/C/005028/R/0011 (without RMP)

Applicant: Accord Healthcare S.L.U.
PRAC Rapporteur: Nathalie Gault
Scope: 5-year renewal of the marketing authorisation

**Action**: For adoption of advice to CHMP

### 8.3.8. Ravulizumab - ULTOMIRIS (CAP) - EMEA/H/C/004954/R/0040 (without RMP)

Applicant: Alexion Europe SAS

PRAC Rapporteur: Kimmo Jaakkola

Scope: 5-year renewal of the marketing authorisation

**Action**: For adoption of advice to CHMP

### 8.3.9. Talazoparib - TALZENNA (CAP) - EMEA/H/C/004674/R/0017 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Carla Torre

Scope: 5-year renewal of the marketing authorisation

**Action**: For adoption of advice to CHMP

### 9. Product related pharmacovigilance inspections

#### 9.1. List of planned pharmacovigilance inspections

None

#### 9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

#### 9.3. Others

None

### 10. Other safety issues for discussion requested by the CHMP or the EMA

#### 10.1. Safety related variations of the marketing authorisation

None
10.2. **Timing and message content in relation to Member States’ safety announcements**

None

10.3. **Other requests**

None

10.4. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. **Other safety issues for discussion requested by the Member States**

11.1. **Safety related variations of the marketing authorisation**

11.1.1. **Methotrexate (NAP) - SE/H/1442/01-02/II/27, SE/H/1422/01/II/20**

**Applicant(s):** Orion Corporation  
**PRAC Lead:** Mari Thorn  
**Scope:** PRAC consultation on type II national variations to update the product information of methotrexate-containing products in order to add a warning on photosensitivity based on the MHRA review of methotrexate and photosensitivity reactions, on request of Sweden  
**Action:** For adoption of advice to Member States

11.2. **Other requests**

None

12. **Organisational, regulatory and methodological matters**

12.1. **Mandate and organisation of the PRAC**

12.1.1. **PRAC membership**

**Action:** For information
12.1.2. **Vote by proxy**

**Action:** For information

12.2. **Coordination with EMA Scientific Committees or CMDh-v**

None

12.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

None

12.4. **Cooperation within the EU regulatory network**

12.4.1. **Health threats and EMA Emergency Task Force (ETF) activities - update**

**Action:** For discussion

12.5. **Cooperation with International Regulators**

None

12.6. **Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee**

None

12.7. **PRAC work plan**

None

12.8. **Planning and reporting**

12.8.1. **EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q4 2023 and predictions**

**Action:** For discussion

12.9. **Pharmacovigilance audits and inspections**

12.9.1. **Pharmacovigilance systems and their quality systems**

None
### 12.9.2. Pharmacovigilance inspections

None

### 12.9.3. Pharmacovigilance audits

None

### 12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

#### 12.10.1. Periodic safety update reports

None

#### 12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead(s): Jana Lukačišinová

**Action:** For discussion

#### 12.10.3. PSURs repository

None

#### 12.10.4. Union reference date list – consultation on the draft list

**Action:** For adoption

### 12.11. Signal management


**Action:** For discussion

#### 12.11.2. Signals and safety analytics project – update on activities

**Action:** For discussion

### 12.12. Adverse drug reactions reporting and additional reporting

#### 12.12.1. Management and reporting of adverse reactions to medicinal products

None
12.12.2. **Additional monitoring**

None

12.12.3. **List of products under additional monitoring – consultation on the draft list**

**Action:** For adoption

12.13. **EudraVigilance database**

12.13.1. **Activities related to the confirmation of full functionality**

None


12.14.1. **Risk management systems**

None

12.14.2. **Tools, educational materials and effectiveness measurement of risk minimisations**

None

12.15. **Post-authorisation safety studies (PASS)**

12.15.1. **Post-authorisation Safety Studies – imposed PASS**

None

12.15.2. **Post-authorisation Safety Studies – non-imposed PASS**

None

12.16. **Community procedures**

12.16.1. **Referral procedures for safety reasons**

None

12.17. **Renewals, conditional renewals, annual reassessments**

None
12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. Covid-19 infection and medicines in pregnancy (CONSIGN) - final study results

PRAC lead(s): Sabine Straus, Ulla Wändel Liminga
Action: For discussion

12.21.2. Direct healthcare professional communications (DHPCs) process review and publication on EMA website

Action: For discussion

12.21.3. Drafting group on multiple sclerosis and and use of disease modifying drugs (DMDs) in women of childbearing potential – update

PRAC lead: Nathalie Gault
Action: For discussion

12.21.4. Drafting group on standard product information wording - Haemophagocytic Lymphohistiocytosis (HLH) -update

PRAC lead: Bianca Mulder
Action: For discussion
12.21.5. **EMA-HMA Lessons Learned from COVID-19 Pandemic**

*Action*: For discussion

12.21.6. **International Conference on Harmonisation (ICH) E2D(R1) - Post-approval safety data management: definitions and standards for expedited reporting - update**

PRAC Lead(s): Sabine Straus

*Action*: For discussion

12.21.7. **Pharmacovigilance business team - activities and work plan**

*Action*: For discussion

12.21.8. **PRAC Assessors trainings - update**

PRAC Lead(s): Martin Huber, Sabine Straus

*Action*: For discussion

12.21.9. **Rules for granting companies extended clock-stops – proposal for review**

PRAC lead: Ulla Wändel Liminga

*Action*: For discussion

13. **Any other business**

Next meeting on: 04-07 March 2024

14. **Explanatory notes**

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

**EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures**

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0)

**Signals assessment and prioritisation**

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive
knowledge of a medicine’s benefits and risks. The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event. The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

**Risk Management Plans (RMPs)**
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

**Assessment of Periodic Safety Update Reports (PSURs)**
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine’s authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

**Post-authorisation Safety Studies (PASS)**
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

**Product related pharmacovigilance inspections**
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

For a list of acronyms and abbreviations, see:
[List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in Pharmacovigilance Risk Assessment Committee (PRAC)]

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)